 
 
 
Protocol I5B -MC -JGDP(e) 
 
 A Phase 1b (Open-Label) / Phase 2 (Randomized, Double- Blinded) 
Study Evaluating Nab -Paclitaxel and Gemcitabine With or Without 
Olaratumab in the Treatment of First -Line Metastatic Pancreatic 
Cancer  
 
 
[STUDY_ID_REMOVED]  
 
 Approval Date: 20 March 2019 
I5B-MC-JGDP(e)Clinical Protocol Page 1
LY3012207Protocol I5B-MC-JGDP(e)
A Phase 1b (Open- Label) / Phase 2 (Randomized, 
Double-Blinded) Study  Evaluating Nab -Paclitaxel and 
Gemcitabine With or Without Olaratumab in the Treatment of
First-Line Metastatic Pancreatic Cancer
Confidential Information
The information contained in this protocol is confidential and is intended for the use of clinical investigators.  It 
is the property of Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_853597] (LY3012207) , unless such persons are bound 
by a confidentiality agreement with Eli Lilly a nd Company or its subsidiaries.
Note to Regulatory Authorities :  This document may contain protected personal data and/or commercial ly 
confidential information exempt from public disclosure.  Eli Lilly and Company requests consultation 
regarding release/redaction prior to any public release.  In the [LOCATION_002], this document is subject to 
Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated 
without the written approval of Eli Lilly and Company or its subsidiaries.
Olaratumab (LY3012207)
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_853609] 15 September 2016.
Amendm ent(a) Electronically Signed and Approved by [CONTACT_229490] 06 December 2016.
Amendm ent (b) Electronically Signed and Approved by [CONTACT_229490] 27 February 2017.
Amendm ent (c) Electronically Signed and Approved by [CONTACT_229490] 04 December 2017 .
Amendm ent (d) Electronically Signed and Approved by [CONTACT_229490] 10 December 2018.
Amendm ent (e) Electronically Signed and Approved by [CONTACT_81098].
Approval Date: 20-Mar-2019 GMT
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188032] ivities....................................................................................................... 11
3.Introduction ...................................................................................................................... 19
3.1.Study Rationale............................................................................................................ 19
3.2.Background .................................................................................................................. 19
3.2.1. Olaratumab.......................................................................................................... 19
3.2.2. Pancreatic Cancers ............................................................................................... 20
3.3.Benefit/Risk Assessment .............................................................................................. 21
4.Objectives and Endpo ints.................................................................................................. 23
5.Study Design..................................................................................................................... 24
5.1.Overall Design ............................................................................................................. 24
5.2.Number of Pat ients....................................................................................................... 28
5.3.End of Study  Definition............................................................................................... 28
5.4.Scientific Rationale for Study  Design........................................................................... 28
5.4.1. Rationale for Amendment (a) ............................................................................... 29
5.4.2. Rationale for Amendment (b) ............................................................................... 29
5.4.3. Rationale for Amendment (c) ............................................................................... 29
5.4.4. Rationale for Amendment (d) ............................................................................... 29
5.4.5.Rationale for Amendment (e) ............................................................................... [ADDRESS_1188033] ions.................................................................................................... 36
6.4.Screen Failures ............................................................................................................. 36
7.Treatments ........................................................................................................................ 37
7.1.Treatments Administered ............................................................................................. 37
7.1.1. Premedication...................................................................................................... 37
[IP_ADDRESS]. Olaratumab/Placebo ........................................................................................ 38
[IP_ADDRESS]. Nab-paclitaxel................................................................................................ 39
[IP_ADDRESS]. Gemcitabine................................................................................................... 39
[IP_ADDRESS]. Granulocyte -Colony Stimulating Factors ........................................................ 40
7.1.2. Investigator Responsibilit ies................................................................................. 40
7.1.3. Packaging and Labelling ...................................................................................... 40
I5B-MC-JGDP(e)Clinical Protocol Page 3
LY30122077.1.4. Dose-Limiting Toxicit y Determination (Phase 1b) ............................................... 41
7.2.Method of Treatment Assignment ................................................................................ 41
7.2.1. Phase 1b............................................................................................................... 42
7.2.2. Phase 2................................................................................................................. 42
7.2.3. Selection and Timing o f Doses............................................................................. 42
7.3.Blinding....................................................................................................................... 43
7.3.1. Emergency  Unblinding ........................................................................................ 43
7.3.2. Inadvertent Unblinding ........................................................................................ 43
7.4.Dosage Modification .................................................................................................... 43
7.4.1. Dosing and Dose Reductions ................................................................................ 44
7.4.2. Dose Modificat ions.............................................................................................. 45
[IP_ADDRESS]. Hematological Toxicites................................................................................. 45
[IP_ADDRESS]. Non-Hematological Toxicities........................................................................ 46
7.4.3. Dose Delays ......................................................................................................... 47
7.4.4. Dosing Discontinuation ........................................................................................ 48
[IP_ADDRESS]. Gemcitabine................................................................................................... 48
[IP_ADDRESS]. Nab-paclitaxel................................................................................................ 48
[IP_ADDRESS].1. Hepatic Impairment.................................................................................. 48
[IP_ADDRESS].2. Sepsis....................................................................................................... 48
[IP_ADDRESS].3. Pneumonitis.............................................................................................. 48
[IP_ADDRESS].4. Infusion-related Reactions/Hypersensit ivity 
Reactions.................................................................................................. 49
[IP_ADDRESS]. Olaratumab..................................................................................................... 49
[IP_ADDRESS].1. Olaratumab Infusio n-Related React ions.................................................... 49
7.5.Preparation/Handling/Storage/Ac countabilit y............................................................... 50
7.6.Treatment Compliance .................................................................................................50
7.7.Concomitant Therapy ................................................................................................... 50
7.7.1. Other Concomitant Medicat ion (CYP2C8 and CYP3A4 
Inhibitors or Inducers) .......................................................................................... 50
7.7.2. Supportive Care ................................................................................................... 50
[IP_ADDRESS]. Colony Stimulat ing Factors ............................................................................ 51
[IP_ADDRESS]. Transfusio n of Blood Product ......................................................................... 51
[IP_ADDRESS]. Antiemetic Therapy ........................................................................................ 51
7.7.3. Prohibited Therapi[INVESTIGATOR_014] ............................................................................................ 51
7.8.Treatment after the End of the Study ............................................................................ 51
7.8.1. Continued Access .................................................................................................51
8.Discontinuati on Criteria.................................................................................................... 53
8.1.Discontinuati on from Study Treatment......................................................................... 53
I5B-MC-JGDP(e)Clinical Protocol Page 4
LY30122078.1.1. Discontinuati on of All Study Treatment............................................................... 53
8.1.2. Discontinuati on of Olaratumab/Placebo ............................................................... [ADDRESS_1188034] ....................................................................... 58
9.2.6. Complaint Handling ............................................................................................. 58
9.3.Treatment of Overdose .................................................................................................59
9.4.Safety........................................................................................................................... 59
9.4.1. Other Safet y Measures ......................................................................................... 59
9.4.2. Safety Monitoring................................................................................................ 59
[IP_ADDRESS]. Hepatic Monitoring........................................................................................ 60
9.5.Pharmacokinet ics......................................................................................................... 60
9.6.Pharmacodyn amics...................................................................................................... 61
9.7.Genetics....................................................................................................................... 61
9.7.1. Whole Blood Samples for Pharmacogenet ic Research .......................................... 61
9.8.Biomarkers................................................................................................................... 61
9.8.1. Samples for Nonpharmacogenet ic Biomarker Research ........................................ 62
9.8.2. Tissue Samples for Research ................................................................................ 62
9.8.3. Immunogenicity Assessments .............................................................................. 63
9.9.Patient-Reported Outcomes/Resource Utilizat ion (Phase 2 only ).................................. 64
9.9.1. Patient-Reported Outcomes .................................................................................. 64
[IP_ADDRESS]. Pain assessments ............................................................................................. 64
[IP_ADDRESS]. EORTC QLQ -30............................................................................................ 65
[IP_ADDRESS]. EQ-5D-5L...................................................................................................... 66
9.9.2. Resource Utilization ............................................................................................. 66
10.Statistical Considerations .................................................................................................. 67
10.1.Sample Size Determinat ion.......................................................................................... 67
10.2.Populations for Analyses .............................................................................................. 67
10.3.Statistical Analyses ...................................................................................................... 68
I5B-MC-JGDP(e)Clinical Protocol Page 5
LY301220710.3.1. Efficacy Analyses ................................................................................................ 68
[IP_ADDRESS]. Primary Endpo int........................................................................................... 68
[IP_ADDRESS]. Secondary  Endpoints...................................................................................... 69
10.3.2. Safety Analyses.................................................................................................... 70
10.3.3. Other Analyses ..................................................................................................... 70
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 70
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 70
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 70
[IP_ADDRESS]. Poststudy-Treatment -Discontinuation Therapy ............................................... 71
[IP_ADDRESS]. Treatment Compliance .................................................................................... 71
[IP_ADDRESS]. Pharmacokinet ic Analyses .............................................................................. 71
[IP_ADDRESS]. Patient Reported Outco mes Analyses -Phase 2 only ....................................... 71
[IP_ADDRESS]. Biomarker Analyses ....................................................................................... 72
[IP_ADDRESS]. Healthcare Resource Utilization ...................................................................... 72
10.3.4. Subgroup Analyses .............................................................................................. 72
10.3.5. Interim Analyses .................................................................................................. 72
11.References ........................................................................................................................ 74
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188035] ion Treatment Guidelines................. 39
TableJGDP.8. Dosing and Dose Reductions for Nab -paclitaxel and Gemcitabine ..........45
TableJGDP.9. Dosing and Dose Reductions for Olaratumab .......................................... 45
TableJGDP.10. Dose Recommended and Modifications for Neutropenia and/or 
Thrombocy topenia within a Cycle .......................................................... 46
TableJGDP.11. Guidelines for Dose Modificat ions due to Non -Hematological 
Study Drugs-Related Toxi cities.............................................................. 47
Table JGDP.12. World Health Organizat ion Pain Scale .................................................... 65
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188036] of Figures
Figure Page
FigureJGDP.1. Illustration of study design of Phase 1b. .................................................. 26
Figure JGDP.2. Illustration of study design of Phase 2. .................................................... 27
Figure JGDP.3. Continued access diagram. ...................................................................... 52
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188037] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 77
Appendix 2. Study Governance, Regulatory , and Ethi cal Considerati ons.................... 82
Appendix 3. Clinical Laboratory  Tests........................................................................ 85
Appendix 4. Pharmacokinet ic, Immunogenicit y, and Biomarker Research 
Sampling Schedule ................................................................................. 87
Appendix 5. Hepatic Monitoring Tests for Treat ment-Emergent Abnormalit y............91
Appendix 6. Creatinine Clearance Formula .................................................................92
Appendix 7. Protocol Amendment I5B -MC-JGDP(e) Summary :  A Phase 1b 
(Open-Label) / Phase 2 (Rando mized, Double -Blinded) Study  
Evaluating Nab-Paclitaxel and Gemci tabine With or Without 
Olaratumab in the Treatm ent of First -Line Metastatic Pancreatic 
Cancer.................................................................................................... 93
I5B-MC-JGDP(e)Clinical Protocol Page 9
LY30122071.Synopsis
Protocol Title:
A Phase 1b (Open -Label) / Phase 2 (Randomized, Double -Blinded) Study Evaluating Nab -Paclitaxel and 
Gemcitabine With or Without Olaratumab in the First-Line Treatment of Metastatic Pancreatic Cancer
Rationale:
Study I5B -MC-JGDP (JGDP) is designed to evaluate the safety and efficacy of ola ratumab in combination with 
nab-paclitaxel and gemcitabine .
Objectives and Endpoints:
Objectives Endpoints
Primary
Phase 1b:
to determine a recommended Phase 2 dose of 
olaratumab in combination with nab-paclitaxel and 
gemcitabine
Phase 2:
to compare the efficacy of olaratumab plus 
nab-paclitaxel and gemcitabine with placebo plus nab-
paclitaxel and gemcitabinePhase 1b
DLTs
Safety (including but not limited to) TEAEs, SAEs, 
and clinical laboratory abnormalities
Phase 2
OS
Secondary
Phase 1b
to characterize the safety and toxicity  profile of 
olaratumab plus nab-paclitaxel and gemcitabine
to evaluate the PKand immunogenicity of olaratumab
plus nab-paclitaxel and gemcitabine
to document the antitumor activity observed with 
olaratumab plus nab-paclitaxel and gemcitabine
Phase 2
to assess time -to-event variables
to document the antitumor activity observed with 
olaratumab plus nab-paclitaxel and gemcitabine
toassess PROs: pain, HRQoL, and health status
to determine safety and tolerability of olaratumab in 
combination with nab-paclitaxel and gemcitabine
to assess the PKand immunogenicity of olaratumab 
plus nab-paclitaxel and gemcitabinePhase 1b
Safety monitoring , including TEAEs, SAE, and deaths
Minimum serum/plasma concentration of olaratumab
plus nab-paclitaxel and gemcitabine
OS, PFS, ORR, and DoR
Phase 2
PFS, DoR
ORR
mBPI-sf, EORTC -QLQ-C30, and EQ-5D-5L
TEAEs, AESI, SAEs, clinical laboratory tests, vital 
signs, physical examinations , hospi[INVESTIGATOR_059], and 
deaths
Minimum serum/pla sma concentration of olaratumab 
plus nab-paclitaxel and gemcitabine
Abbreviations:  AE SI=adverse event of special interest ; DLT=dose-limiting toxicity; DoR = duration of response; 
EORTC = European Organisation for Research and Treatment of Cancer HRQoL=Health-related Quality of Life; 
mBPI-sf= modified brief pain index -short form; ORR=objective response rate; OS = overall survival; PFS = 
progression -free survival; PK =pharmacoki netic; PRO = patient -reported outcomes; SAE=serious adverse even ts; 
TEAE=treatment-emergent adverse events.
Overall Design:
Study JGDP is an open -label, multicenter, nonrandomized Phase 1b study of olaratumab in combination with nab -
paclitaxel and gemcitabine followed by a randomized, double -blinded, placebo-controlled, Phase 2 study of 
I5B-MC-JGDP(e)Clinical Protocol Page 10
LY3012207olaratumab plus nab -paclitaxel and gemcitabine versus placebo plus nab -paclitaxel and gemcitabine in patients with 
metastatic (Stage IV) unresectable pancreatic cancer , who havenotreceived priortreatmentfor metastatic disease.
Number of Patients:
Entered: Approximately 207(Phase 1b : 27;Phase 2: 180)
Enrolled/Randomized (1:1 randomization [Phase 2 only ]): 186(Phase 1b: 24; Phase 2: 162)Phase 1b:
Approximately 24 patients evaluable for dose -limiting toxicities (DLTs). Patients who are not evaluable 
for DLTs will be replaced.
Phase 2:  approximately 81patientsper treatment arm
Treatment Arms and Duration:
All patients enrolled in this study will receive olaratumab/placeboadministered via intravenous (I.V.)infusionin 
combination withnab-paclitaxel and gemcitabine.   After study completion, patients on study treatment who continue 
to experience clinical benefit and no undue risks, in the opi[INVESTIGATOR_871], may continue to receive study 
treatment until one o f the criter ia for discontinuation is met (see Section 8for details).
Postdiscontinuation Follow -Up Period Assessments
Terms used to describe the postdiscontinuation of study treatment are defined below:
Postdiscontinuation Follow -Up:  begins the day after the patient and the investigator agree that the patient 
will no longer continue study treatment.
oThe short -term follow -up period begins the day after the patient and the investigator agree that the 
patient will no longer continue study treatment and lasts approximately 30 days.
oThe long-term follow -up period begins 1 day after the short -term follow -up period is completed and 
continues until death or end of trial.
Continued Access/ Follow -Up
The continued access period will apply to this study as long as 1 patient is still on study treatment when study 
completion occurs.  Lilly will notify investigators when the continued access begins.  Continued access follow -up 
(Visit 901) begins 1 day after the patient and the investigator agree that the patient will no longer continue treatment 
in the continued access period and lasts approximately 30 days .
Study Schedule of Activities (Section 2) describe sall assessments for the postdiscontinuation , continued access, and 
follow-up periods .
Study Completion and End of Trial
This study wil l be considered complete following the final analysis /evaluation of OS after approximately 113events 
(deaths) have been recorded .
The end of trial occurs after study completion and after the last patient has discontinued from the study for oneof 
the following reasons:   death,lost to follow-up,patient or investigator decis ion to withdraw the patient, or Lilly 
decision to stop the study.   Investigators will continue to follow the study schedule of activities for all patients until 
notified by [CONTACT_853610].
I5B-MC-JGDP(e)Clinical Protocol Page 11
LY30122072.Schedule of Activities
TableJGDP.1. Baseline Schedule of Activities
Relative Day Prior to C1D1 28[ADDRESS_1188038] be signed before any protocol-specific 
procedures are performed.
Physical exam ination X Including height, weight, and vital signs 
(temperature, blood pressure, pulse rate, and 
respi[INVESTIGATOR_1487])
ECOG per formance status X (Oken et al. 1982) Refer to Section6.1
Medical history X Including assessment of preexisting conditions , 
historical illnesses , and substance usage (such as 
tobacco,alcohol, or caffeine)
Priorand current medication X Current medications (including analgesic use) and 
those received within [ADDRESS_1188039] 1.1 ( Eisenhauer et al. 
2009).
Spi[INVESTIGATOR_853598], 
chest, and pelvisas clinically indicated
On scans available , assess for presence of lung, 
liver, bone and brain metastases. 
Radiologic assessments obtained prior to the date of 
consentmay be used if performed within [ADDRESS_1188040] XApplies only to women of childbearing potential.  
See Appendix 3 for designation of local or central 
testing.
I5B-MC-JGDP(e)Clinical Protocol Page 12
LY3012207PRO assessment ( mBPI-sf) 
Phase [ADDRESS_1188041] cycle prior to study 
treatment administration.  Questionnaires should be 
administered to the patient prior to extensive 
interaction with site staff.  See Section 9.9
Tumor Tissue (archival or newly 
obtained biopsy)X Any time prior to the first infusion .  Optional 
collection for Phase 1b, mandatory collection for 
Phase 2. See Section 9.8.2
Abbreviations:  AE = adverse event; C1D1 =Cycle 1 Day 1; CTCAE =Common Terminology Crite ria for Adverse 
Events; ECG=electrocardiogram; ECOG= Eastern Cooperative Oncology Group; ICF =informed consent form ; 
mBPI-sf= modified Brief Pain Inventory -short form ; PRO = patient -reported outcome; RECIST1.1 =Response 
Criteria In Solid Tumors Version 1.1 (Eisenhauer et al. 2009).
I5B-MC-JGDP(e)Clinical Protocol Page 13
LY3012207TableJGDP.2. On-Study-Treatment Schedule of A ctivities
Cycle1 and beyond
Day within Cycle(±3 days) D1 D8 D15 D22
(Phase 1b
Only)
Instructions Procedure
Physical examination X Symptom-directed examination
Perform prior to administration of study drug(s).
Including weight, height, and vital signs ( temperature, blood pressure, pulse rate, 
and respi[INVESTIGATOR_1487] )
Concomitant medication X X X XaRefer to Section 7.7
AE collection X X X XaRefer to Section 9.2.2
ECOG performance status X Refer to Section 6.1
Radiologic imaging and 
measurement of palpable or visible
lesionsX Perform according to RECIST 1.1, by [CONTACT_853611], every 8 
weeks(±7days),from the start of study treatment in Phase [ADDRESS_1188042]. (See Section 5.1)
Perform as scheduled, even if study treatment is delayed or omitted.
Spi[INVESTIGATOR_853599], chest, and pelvis as clinically 
indicated
At PD, assessscans available for presence of tumor lesions in lung, liver, bone and 
brain
ECG X Cycle 1 only .  Perform additional evaluations in the setting of cardiac symptoms and/or 
at the discretion of the investigator .  Refer to Section 9.4.1
Hematology X X X Xa3days prior to administration of study treatment, unless more frequent assessment is 
clinically indicated .  See Appendix 3
Coagulation X Perform within 3 days prior to administration of study treatment on Day 1 of every 
other cycle , unless mo re frequent assessment is clinically indicated .  See Appendix 3
Clinicalchemistry X X X Xa3days prior to administration of study treatment, unless more frequent assessment is 
clinically indicated . CA-19.[ADDRESS_1188043].  Applies only to women of childbearing potential .  
Perform on Day 1 of each cycle or per local practice (whichever is shorter duration).  If 
the urine pregnancy test performed on Day [ADDRESS_1188044] (pregnancy test results are not recorded on the eCRF).
I5B-MC-JGDP(e)Clinical Protocol Page 14
LY3012207Cycle1 and beyond
Day within Cycle(±3 days) D1 D8 D15 D22
(Phase 1b
Only)
Instructions Procedure
PRO assessment s (mBPI-sf; 
EQ-5D-5L;EORTC QLQ C30 )-
Phase [ADDRESS_1188045], followed by [CONTACT_20368] -C30 and continuing with the EQ -5D-5L.See 
Section 9.9.1
Administer olaratumab X X X Phase 1b, Cohorts 1 and2,administered I.V. on Days 1, 8, and 15.  Cohorts 3 and4,
administered I.V. on Days 1 and 15.   
For Phase 2portion, olaratumab will be administered on Days 1, 8 and 15. For 
additional detail, (see TableJGDP.6).
Administer nab -paclitaxel X X X See Section 7.1
Administer gemcitabine X X X See Section 7.1
Sample collection for
X For all sample collection, s ee Appendix 4 .Pharmacodynamics /Biomarkers
Pharmacokinetics
Immunogenicity
Pharmacogenomics
Abbreviations:  AE = adverse event; CTCAE =Common Terminolo gy Criteria for Adverse Events; D = Day; ECG=electrocardiogram; ECOG =Eastern Cooperative 
Oncology Group ; EORTC = European Organisation for Research and Treatment of Cancer; EQ = EuroQol; IG = immunogenicity; I.V.=intravenous(ly) ; 
mBPI-sf=modified Brief Pain Inventory -short form ;PD=progressive disease; PG = pharmacogenomics; PK = pharmacokinetic s; PRO = patient -reported outcome ; 
RECIST 1.1 =Response Criteria In Solid Tumors Version1.1.
aActivities performed only in the Phase 1b portion of the study.  Omit for the Phase 2 port ion.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188046]-Study-Treatment Follow -Up Schedule of Activities
ProcedureShort-Term 
Follow-UpaLong-Term 
Follow-UpbInstructions
Physical exam ination X Including weight, and vital signs ( temperature, blood pressure, pulse rate, 
and respi[INVESTIGATOR_1487] )
Concomitant medication X Refer to Section 7.7
AE collection X Refer to Section 9.2.2
ECOG per formance status X Refer to Section 6.1
Radiologic imaging and measurement of 
palpable or visible lesionsX X For patients who discontinue study treatment for reasons other than 
documented radiographic disease progression , imaging studies and tumor 
assessments are to be obtained q8 weeks (7days)according to
RECIST1.1(See Section 5.1),irrespective oftreatment cyclesascalculated
fromenrollment inPhase1borfromrandomization forPhase2, until:
the patient has documented radiographic disease progression ,or
studycompletion , or
start of a new anticancer therapy
After the patient has documented disease progression, radiologic tests are no
longer required.
Spi[INVESTIGATOR_853599], chest, and pelvis as 
clinically indicated
At PD, as sess scans available for presence of tumor lesions in lung, liver, 
bone and brain
ECG X See Section 9.4.1
Collection of survival information X Perform q12 weeks (±14days).  Although preferable to collect during a 
clinic visit, survival information may be collected by [CONTACT_853612] (for example, via telephone).  
Collection of post -study-treatment anticancer 
therapy informationX X Perform q12 weeks(±14days) for the first 2 years after discontinuation 
from study treatment and q6 mo (±14 days) thereafter until death or study 
completion.
Hematology X See Appendix 3
Coagulation X See Appendix 3
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188047] 
(pregnancy test results are not recorded on the eCRF). Additional pregnancy 
tests may be done after short -term follow -up if required by [CONTACT_1295] .
Clinicalchemistry X See Appendix 3
Urinalysis X
PRO assessment s (mBPI-sf; EQ-5D-5L;
EORTC QLQ C30 )
Phase [ADDRESS_1188048] long-
term follow-up visit.  The PROs should be completed in the order described 
for the short-term follow-up visit.  The completed PROs should be placed in 
an envelope addressed and stamped for return to the study site. If long-term 
follow-up visit is conducted via a phone call, ever y effort should be made 
for the patient to complete the questionnaires during the call , preferably 
before other study questions are asked .Once completed, the questionnaires 
should be mailed or returned back to the site as soon as possible.
Sample collection for: X
For all sample collection, s eeAppendix 4 .Pharmacodynamics/Biomarkers
Pharmacokinetics
Immunogenicity
Pharmacogenomics
Abbreviations:  AE =adverse event; CTCAE =Common Terminology Criteria for Adverse Event; ECOG=Eastern Cooperative Oncology Group; eCRF=electronic 
case report form; EORTC = European Organisation for Research and Treatment of Cancer; EQ = EuroQol; mBPI-sf=modified Brief Pain Inventory -short form; 
PD=progressive disease; PRO = pat ient-reported outcome; q =every; RECIST 1.1 =Response Criteria In Solid Tumors Version1.1.
I5B-MC-JGDP(e)Clinical Protocol Page 17
LY3012207aShort-term follow -up begins the day after the patient and the investigator agree that the patient will no longer continue study treatment and l asts approximately 
30days (±7 days).  If it is deemed to be in the best interest of the patient to start a new anticancer treatment prior to the scheduled end of t he follow -up visits, the visit 
duration may be shortened. In this case, the follow -up assessment s should be completed prior to the initiation of the new therapy.
bLong-term follow -up period begins theday after the short -term follow -up period is completed and continues until the patient’s death or overall study completion.
Follow-up should be attem pted at regularly scheduled intervals ( q 12 weeks [±14days]). This follow -up might be conducted via a request to the patient’s doctor or by 
[CONTACT_121944], his/her family by [CONTACT_756]/mail.  No follow -up procedures will be performed for a patientwho withdraws informed consent unless he or she 
has explicitly provided permission and consent to allow for follow -up.
I5B-MC-JGDP(e)Clinical Protocol Page 18
LY3012207TableJGDP.4. Continued A ccess Schedule of A ctivities
Study Treatment Follow-Upa
Visit 501-5XX 901
Procedure b Instructions
AE collection X X Refer to Section 9.2.2
Pharmacokinetics and Immunogenicity X X Only if a patient experiences an IRR, collectblood samples for PK and 
IG analysis at the following time points:  (1) as soon as possible after 
the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 days 
after the IRR.
Administer study drugs X
Abbreviations:  AE =adverse event; CTCAE = Common Terminology Criteria for Adverse Events; IG = immunogenicity; IRR =infusion-related reaction ; 
PK=pharmacokinetics .
aContinued access follow -up begins [ADDRESS_1188049] of the patient to start a new anticancer treatment prior to the s cheduled end of 
the follow -up visits, the visit duration may be shortened. In this case, the follow -up assessments should be completed prior to the initiation of the new therapy.
bEfficacy assessments will be done at the investigator’s discretion based o n the standard of care.
I5B-MC-JGDP(e)Clinical Protocol Page 19
LY30122073.Introduction
3.1.Study Rationale
Study I5B-MC-JGDP (JGDP)isa Phase 1b/2 trial designed to evaluate the safet y and efficacy  of 
olaratumab in combination with nab-paclitaxel and gemcitabine in pat ients with unresectable 
metastatic pancreatic cancer , who had not previously been treated for metastatic disease .
Platelet-derived growth fa ctor receptor (PDGFR)/ platelet-derived growth factor ( PDGF)
signaling has been shown to be an important signaling regulator in epit helial mesenchymal 
transition in several  types of cancer .  Platelet-derived growth factor receptor /platelet-derived 
growth factorsignaling has been shown to create anautocrine signaling loop in pancreat ic cancer 
that is an act ive participant in the format ion of desmoplast ic reactionas well as the activat ion of 
pancreatic stellate cells –hallmarks of pancreatic cancer and i mportant contributors to the 
pancreatic cancer microenvironment ( Mahadevan and Von Hoff 2007 ).  Thus, the use of 
neutralizing monoclonal antibodyspecific to human PDGFRα could provide atherapeutic target
in metastatic pancreat ic cancer.
Across numerous cancers evaluated based on data fro m The Cancer Geno me Atlas (TCGA) 
research, overexpressio n of PDGFRα in tumors relative to normal t issue was highest in soft 
tissue sarco ma(STS) (37.1% overexpressio n)and pancreat ic cancer (41.1% overexpressio n).  
Overexpression of PDGFRα ligands (PDGF -A, -B, and -C) wasobserved in sarcoma relat ive to 
normal tissue(PDGF-A 7.6%, PDGF -B 6.7%, and PDGF -C 20%).  Though little to no 
overexpressio n was observed in pancreatic cancer tumors relative to normal pancreas tissue 
(PDGF-A 0%, PDGF -B 0%, and PDGF -C 5.4%), expressio n levels in normal pancreas were 
notably higher than expressio n levels in normal soft tissue, suggest ing that despi[INVESTIGATOR_853600] n of PDGF ligands in pancreat ic tumors, there are PDGF ligands p resent and 
overexpressio n of PDGFRα demonstrates necessary co mponents for PDGF signaling with in the 
tumor microenvironment.
Tissue arrayfrom human pancreat ic cancer tumors show that while not direct ly expressed on the 
tumor, PDGFRα is expressed in pancrea tic cancer tum or stroma (9 of 12 samples)(data in-
house).  The strong stromal co mponent to pancreatic cancer and the associated PDGFRα staining 
seen may provide an opportuni ty to disrupt the tumor growth and support provided by  [CONTACT_853613]α 
signaling by  [CONTACT_853614]α in pancreat ic cancer and its associated tumor stroma 
(Olaratumab Bi oinformatic Study  Report 2015 ).
3.2.Background
3.2.1.Olaratumab
Olaratumab is a recombinant human immunoglobulin G subclass 1 (IgG1) -type monoclonal 
antibody that binds to PDGFRα.  This anti body possesses high affinit y binding for PDGFRα and 
blocks PDGF -AA, -BB, and -CC from binding to the receptor.  In addit ion to blocking ligand-
induced cell mitogenesis and receptor autophosphorylat ion, olaratumab inhibits ligand -induced 
I5B-MC-JGDP(e)Clinical Protocol Page 20
LY3012207phosphorylat ion of the downstream signaling mo lecules Akt and mitogen -activated protein
kinase(Loizoset al. 2005).
In 2 Phase 1 dose -escalation trials in patients with solid tumors (I5B-IE-JGDC and I5B-IE-
JGDF) and in the 2 Phase 2 monotherapy  studies (I5B-IE-JGDE[glioblastoma]and I5B-IE-
JGDH[GIST]), single-agent olaratumab has consistently been well tolerated, with no dose -
limiting toxicit ies (DLTs) observed up to a dose of 20 mg/kg administered every 2 weeks (q2w)
and up to a dose of 16mg/kg administered weekly for 4 weeks fo llowed by 2 weeks off 
treatment for observati on. Olaratumab has been safely  administered in combinat ion with 
liposomal doxorubi cin in Study  I5B-MC-JGDA (olaratumab 20 mg/kg q2w)in patients with 
ovarian cancer , and with paclitaxel/carbopl atin in Study I5B-IE-JGDB (olaratumab 15 mg/kg on
Days1 and 8of a3-weekcycle)in patients with NSCLC .  However, certain tox icities,such as 
neutropeni a and infect ions,were observed at a higher rate for olaratumab plus chemotherapy 
compared with the chemotherapy alo ne.
In the randomized, double -blind Phase 2 study  (I5B-MC-JGDG[JGDG]) in patients with so ft 
tissue sarco ma (STS) , the combinat ion of olaratumab and doxorubicin had an acceptable, 
monitorable, and m anageable safet y profile even in light of a significantly higher median 
cumulative doxorubicin exposure in the olaratumab plus doxorubicin arm.  An increase in 
neutropeni a, but not in neutropenic sepsis or febrile neutropenia, has been observed in the 
olaratumab plus doxorubi cin armcompared with doxorubicinalone. A higher rate of so me 
known doxorubicin -inducedtoxicities, such as , mucositis, nausea/vo miting, and diarrhea ,in the 
olaratumab plus doxorubi cin armwas observed ; however, these toxicit ies were readily  monitored 
and manageable and were predominant ly Grade ≤2in severity.
The combinat ion of olaratumab and doxorubicin resulted in a statist ically significant and 
clinically meaningful improvement in median overall survival (OS; 11.8 -month improvement; 
hazard ratio [ HR]= 0.463, p=0.0003) .  An improvement in median progression -free survival 
(PFS) of2.5 monthswas observed for olaratumab plus doxorubicin over doxorubi cin alone;
(stratified HR=0.672 ,p=0.0615 ) and the study met the protocol-defined significance level for the 
primary endpoint .Exposure -response analysis from StudyJGDG showed that when trough 
concentration at the end of the first cy cle (Cmin1) was used as the pharmacokinet ic (PK)endpoint, 
the model predicted an minimum half -maximal effective concentration at the end of the firs t 
cycle (EC min150) of approximately 66 μg/mL, which corresponds to the 25th percentile of C min1
in the JGDG populat ion.  Patients with Cmin1concentrati ons below theECmin150 progressed 
earlier and had shorter OS than patients with Cmin1above the EC min150.
3.2.2.Pancreatic Cancers
Pancreatic cancer is the fourth leading cause of cancer -relateddeath in the [LOCATION_002] ( US;
ACS2016).Incidence rates in both sex are highestin North America and Europe and lowestin
Asia and Africa (World Cancer Research Fund Internat ional [WWW]) .  In 2016, the number of 
new cases and deaths of pancreat ic cancer in the U Sfor both sexes areestimated to be 53,070 
and 41,780, respectively (Siegel et al. 2016).  In 2013, there were estimated to be 9,4 08 new 
I5B-MC-JGDP(e)Clinical Protocol Page 21
LY3012207cases of pancreatic cancer in the United Kingdo m ([LOCATION_006]) in 2013 and 8817 deaths in 2014 ( Cancer 
Research [LOCATION_006] [WWW]).
Pancreatic ductal adenocarcinom aand its variants account for more than 90% of pancreat ic 
malignancies (Temperoet al. 2010 ).  Difficult y in early detection is a significant factor in the 
overall poor prognosis for patients with pancreat ic cancer.  At the time of diagnosis, the tumor 
that is confined to the pancreas i s fewer than 10%,and over 50% have distant spread (Howard 
1996), limiting the number of patients who are able to seek surgical resect ion as a treatment 
option.
Gemcitabine was approved by  [CONTACT_853615] [ADDRESS_1188050] -line metastatic pancreat ic 
patients.  Since that time, 2 regimens, FOLFIRINOX (Conroy et al. 2011) and gemcitabine plus 
nab-paclitaxel(Von Hoff et al. 2011, 2013) , have supplanted gemcitabine as the current standard 
of care for fi rst-line metastatic pancreat ic cancer for patients with good performance status (0 -1).  
Nab-paclitaxel in combinat ion with gemcitabine was approved in the US in 2013 and in the 
European Union (EU)in 2014 for use in patients wit h metastatic pancreat ic cancer.  
The high-level results of the rando mized Phase 3 clinical trial conducted in 861 patients with 
metastatic pancreatic cancer, whichcompared gemci tabine with a combinat ion of gemcitabine 
and nab-paclitaxel(Von Hoff et al . 2013), demonstrated a median OS of8.5months in the 
gemcitabineplusnab-paclitaxelarm compared with 6.7 months in the gemcitabine alone.  The 
HR for death was 0.72 (95% CI:  0.62 to 0.83; p<.001).  Other end points, including PFS and 
response rate (RR), were superior with the combinati on.  Grade ≥ 3 neutropenia occurred in 38% 
of the patients treated with gemcitabine plus nab -paclitaxel, with 3% of these instances result ing 
in febrile neutropenia.  Twent y-six percent of the patients received growth factors (GFs).  
Cumulative peripheral neuropathy  occurred in 17% of the patients treated with gemcitabine plus 
nab-paclitaxel, and i t was managed wi th temporary discont inuation of nab-paclitaxel fo llowed by 
a reduction in dose.   Despi[INVESTIGATOR_853601] , 
there is still a poor prognosis for patients with metasta tic disease as evidenced by a 5- year 
survival rate that is less than 3% ( SEER 2016 ).
3.3.Benefit/Risk Assessment
Olaratumab has demo nstrated efficacy i n combination with doxorubi cin in pat ients with STS.  
Pancreatic cancer, like STS, is another highly stromal tumor type and preclinical data has 
suggested increased PDGFRα levels in malignant pancreat ictissue, suggest ing olaratumab may 
be able to affect P DGFR signaling in pancreat ic cancer.  Olaratumab has been used in several 
studies in combinat ion with chemotherapi[INVESTIGATOR_853602],with some 
increase in hematologic toxicit y observed.  The current study  will evaluate the safet y of 
olaratumab in combination with nab-paclitaxeland gemcitabine.  Weekly  monitoring of 
hematologic parameters will be conducted to ensure patient saf ety during the dose 
escalation/Phase 1b portion of the study .  The Phase [ADDRESS_1188051] of 
care treatm ent in this study . 
I5B-MC-JGDP(e)Clinical Protocol Page 22
LY3012207More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated advers e events (AEs) of olaratumabare to be found in th e 
Investigator’s Brochure (IB).
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188052] ives and endpo ints ofthe study.
TableJGDP.5. Objectives and Endpoints
Objectives Endpoints
Primary
Phase 1b:
to determine a recommended Phase 2 dose of 
olaratumab in combination with nab -paclitaxel and 
gemcitabine
Phase 2:
to compare the efficacy of olaratumab plus nab -
paclitaxel and gemcitabine with placebo plus 
gemcitabine and nab -paclitaxelPhase 1b
DLTs
Safety (including but not limited to) TEAEs, SAEs, and 
clinical laboratory abnormalities
Phase 2
OS
Secondary
Phase1b
to characterize the safety and toxicity profile of 
olaratumab plus nab -paclitaxel and gemcitabinePhase1b
Safety monitoring, including TEAEs, SAE, and deaths
to evaluate the PKand immunogenicity of olaratumab 
plus nab-paclitaxel and gemcitabine
to document the antitumor activity observed with 
olaratumab plus nab -paclitaxel and gemcitabineMinimum serum/plasma concentration of olaratumab 
plus nab-paclitaxel and gemcitabine
Anti-drug antibody concentration
OS, PFS, DoR, ORR
Phase 2
to assess time -to-event variablesPhase 2
PFS, DoR
to document the antitumor activity observed with 
olaratumab plus nab -paclitaxel and gemcitabineORR
to assess the following PROs: mBPI-sf, EORTC -QLQ-C30, and EQ-5D-5L
to determine safety and tolerability of olaratumab in 
combination with nab-paclitaxel and gemcitabineTEAEs, AESIs, SAEs, clinicallaboratory tests, vital 
signs, physical examinations , hospi[INVESTIGATOR_602] , and 
death
toassess the PK and immunogenicity of olaratumab 
plus nab-paclitaxel and gemcitabineMinimum serum /plasma concentration of olaratumab 
plus nab-paclitaxel and gemcitabine
Anti-drug antibody concentration
Tertiary/Exploratory
tocharacterize tumor tissue and blood biomarkers 
relevant to study drugs including but not limited to 
immune cells/immune and tumor microenvironment
functioning, mechanism of action of study drug s, 
cancer-related pathways, and disease state
to assess the rel ationship between biomarkers and 
clinical outcome sMarkers of immune function, tumor 
microenvironment , drug targets, signaling pathways, 
and disease status
Abbreviations:  AESIs =adverse events of special interest; DLT = dose -limiting toxicity; DoR = duration of 
response; EORTC = European Organisation for Research and Treatment of Cancer; EQ = EuroQol; HRQoL = Health-
related Quality of Life; mBPI-sf = modified Brief Pain Inventor y -short form;ORR = objective response rate; 
OS=overall survival ; PFS=progression-free survival; PK =pharmacokinetics; PRO = patient -reported 
outcome; SAEs=serious adverse events; TEAEs =treatment-emergent adverse events.
I5B-MC-JGDP(e)Clinical Protocol Page 24
LY30122075.Study Design
5.1.OverallDesign
StudyJGDPis Phase 1b/[ADDRESS_1188053] of an open -label,
dose-finding study  and the Phase 2 portion will bea multicenter,randomized, double-blind, 
parallel, placebo -controlled study in patients with metastatic unresectable pancreatic cancer 
(Stage IV) , who havenot received prior treatmentfor metastatic disease.
Phase 1b :
The Phase 1b will co mmence prior to Phase 2. Study cycleswill be 28days in duration. 
In the Phase 1b portion of the study ,a 3 + 3 dose escalat ion design will be used to evaluate the 
safety and tolerabilit y of olaratumab in combinat ion with gemcitabine and nab -paclitaxel in 
patients with pancreatic cancer and determine a recommended Phase 2 dose of olaratumab.  
Three patients will be treated init ially at each dose level.  If no DL Ts occur i n a cohort of 
3patients, a new cohort of 3 patients will be treated at the next higher dose level.  If 1 of 
3patients at any  dose level experiences a DLT, that cohort will be expanded to 6 patients.
If no further patient experiences a DLT, the dose escalat ion can proceed.
If a DLT is observed in ≥2 out of a maximum of 6 patients at any  given dose, 
dose escalat ion will cease and the next lower dose will be the maximum tolerated
dose (MTD).
The dose escalat ion can proceed if fewer than 2 out of 6 evaluable pat ients 
experience a DLT.
During the dose escalat ion, no more than one cohort will be open for enrollment at any  given 
time. 
After the MTD has been ident ified in the dose -escalation phase, approximately 9patients will be 
enrolled in a cohort e xpansion.  The purpose of the cohort expansion is to confirm the safet y of 
the MTD in approximately 12 to 15 patients (including those in the dose escalation cohort) prior 
to proceeding to the Phase 2 portion of the study .  Continuous evaluation of toxicit y in the cohort 
expansion will be performed throughout enrolment in the cohort. If the rate of DLT -like events 
exceeds 33% in the first cy cle, the findings will be discussed, and further enrolment may be 
interrupted. If the expansio n cohort i s discontinued because of toxicit y, a new cohort may  be 
initiated at a previously tested lower dose level.
In the first cohort, olaratumab will be dosed on Days 1, 8, and 15 (that is, on the same days as 
nab-paclitaxeland gemci tabinedosing as described in their [LOCATION_002] Package Insert [ USPI]
and Summaryof Product Characteri stics [SmPC]) at a starting dose of 15 mg/kg.  If the 
15mg/kg dose of olaratumab is tolerated, enrollment will co mmence in Cohort 2 at the 20mg/kg 
dose of olaratumab dosed on Day s 1, 8, and 15.  If the 20 mg/kg dose is tolerated ,approximately 
9to 12additional patients will be enrolled in the cohort expansio n to confirm the safet y and 
tolerability of the dose.
I5B-MC-JGDP(e)Clinical Protocol Page 25
LY3012207If the Cohort 1 olaratumab dose of 15 mg/kg on Days 1, 8, and 15 is not tolerated, dosing of 
olaratumab at 20 mg/kg on Days 1 and 1 5 may be evaluated (Cohort 3) to determine if 
decreasing the frequency  of olaratumab dosing improves the tolerabilit y of olaratumab in 
combination with nab-paclitaxel and gemcitabine (see FigureJGDP.1).  The dose of 20 mg/kg on 
Days1 and 15 will decrease the total dose administered in the cycle from 15 mg/kg dosed on 
Days 1, 8 ,and 15 (in Cohort 1) while st ill providing exposures above th e ECmin150(see 
Section5.5for further dose j ustification).  If the 20mg/kg dose of olaratumab is tolerated, 
enrollment will commence with planned dose escalat ion to 25 mg/kg olaratumab on Days 1 and 
15in the subsequent dose cohort (Cohort 4) .  If neither of the initial doselevels in the Day  1, 8, 
and 15 dosing schedule (Cohort 1) and the Day s1 and 15 dosing schedule (Cohort 3) are 
tolerated,enrollment in the study  will be stopped.
I5B-MC-JGDP(e)Clinical Protocol Page 26
LY3012207Abbreviations:  D = Day; MTD = maximum tolerateddose. 
Note:  Approximately  24patients will be enrolled into the Phase 1b.  A 3 + [ADDRESS_1188054] igators and Lilly clinical 
research personnel.Phase 1b
3 + 3 Dose Escalation Method
Open-Label 
(N=24)
Cohort 1
Olaratumab : 15 mg/kg 
D1, D8, & D15
Nab-pac/gem  D1 , D8, & D1528-Day cycle
Cohort 2
Olaratumab : 20 mg/kg 
D1, D8, & D15
Nab-pac/gem  D1 , D8, & D15
Cohort 3
Olaratumab : 20 mg/kg D1 & D15
Nab-pac/gem  D1 , D8, & D15Cohort 4
Olaratumab : 25 mg/kg D1 & D15
Nab-pac/gem  D1 , D8, & D15Cohort 1 
tolerated
Cohort 1 not 
toleratedCohort Expansion
To enroll approximately 
9 patients at the MTD
Cohort 3 
tolerated
I5B-MC-JGDP(e)Clinical Protocol Page 27
LY3012207Phase 2:
The Phase 2 portion of the study  is a 1:1 randomized, double -blinded, 2-arm study  of olaratumab
at a dose and schedule determined fro m Phase 1b in combination wit h nab-paclitaxeland 
gemcitabine(Treatment Arm)versus placebo plus nab-paclitaxel-gemcitabine (Control Arm)
(see Section 5.4.4).  Patientswill receive nab-paclitaxel (125 mg/m2) via infusio n followed by 
[CONTACT_35421](1000mg/m2)infusion on Days1, 8, and 15of each 28-day cycle.  Nab-paclitaxel 
and gemcitabine will be administered fo llowing olaratum ab/placebo administration.
Patientswillreceive the study  treatment until disease progression or a criterion for 
discontinuat ion is met.  The primary end po int is OS; secondary  end points are PFS, duration of 
response ( DoR), objective response rate ( ORR), patient-reported outcomes ( PROs), and safet y.
Patients will be assessed for tumor response every 8weeks. Patients without disease progressi on 
may continue to receive treatment until the develo pment of unacceptable tox icity, death, orother 
discontinuat ion criteria are met.
Figure JGDP.2illustrates the study  designof Phase 2.
Abbreviations:  D = Day; IV = intravenous; N = number of patients.
Note:  Dose and schedule of olaratumab will be determined based upon tolerability in 
the Phase 1b portion of the study .
Figure JGDP.2. Illustration of study design of Phase [ADDRESS_1188055] igator, may cont inue to receive study treatment 
(Continue dAccess period) until one of the criteria for discont inuation is met, asdescribed in Phase 2
Randomized, Double -Blind
(N=162)
R
A
N
D
O
M
I
Z
ETreatment Arm (N=81)
Olaratumab *
Nab -paclitaxel (125mg/m 2) D1, D8, & D15
Gemcitabine (1,000 mg/m 2)  D1, D8, & D15
Control Arm (N=81)
Placebo (equivalent IV infusion)*
Nab -paclitaxel (125mg/m 2) D1, D8, & D15
Gemcitabine (1,000 mg/m 2)  D1, D8, & D1528-Day cycle
1:1
* Dosing regimen is based on Phase 1b results .
Patients will continue treatment until disease progression or chemotherapy -
related toxicity leading to discontinuation 
I5B-MC-JGDP(e)Clinical Protocol Page 28
LY3012207Section 7.8.1. A continued access fo llow-up visit will occur 30 days (±7 days) after 
discontinuation.
5.2.Number of Patients
Planned enrollment for each phase is as fo llows:
Phase 1b:  Approximately  24patientswith metastatic pancreat ic cancer who have not received 
chemotherapy for metastati c disease will be evaluated for dose-limiting toxicit ies (DLTs).  
Patients who are not evaluable for DL Ts will be replaced .
Phase 2:  Approximately 162patients with metastatic pancreat ic cancer who ha venot received 
chemotherapy for metastati c disease will be randomized in a 1:1 ratio to receive either 
olaratumabplus nab-paclitaxel and gem citabine (Treatm ent Arm) or placebo plus nab-paclitaxel 
and gemcitabine (Control Arm).
5.3.End of StudyDefinition
End of the studyis the date of the last visit or last scheduled procedure for the last patient.
5.4.Scientific Rationale for Study Design
Pancreaticcancer is the fourth leading cause of cancer -relateddeath in the [LOCATION_002] (US; 
ACS2016). Gemcitabine plus nab -paclitaxel (Von Hoff et al. 2011, 2013) and FOLFIRINOX 
(Conroyet al. 2011) are the [ADDRESS_1188056]- line metastatic 
pancreatic cancer for patients with good performance status (0 -1). Despi[INVESTIGATOR_853603], there is st ill a poor prognosis for patients with 
metastatic disease as evidenced by a 5 -year survival rate that is less than 3% ( SEER 2016 ).
Pancreatic cancer is characterized by a highly stromal tumor microenvironment that is co mposed 
largely of extracellular m atrix proteins, fibroblasts, and pancreatic stellate cells.  This tumor 
microenvironment, ordesplasmic react ion, has been associ ated with worse clinical outcomes in 
pancreatic cancer (Erkan et al .2008) as well as other tumors (Hasebe et al .1997). PDGFRα 
expressio n has been shown to be upregulated in malignant pancreas relat ive to normal t issue 
(Ebert et al .1995).  PDGF/PDGFRα signaling in the microenvironment may  contribute to both 
the growth and maintenance of the dense tumor microenvironment as well as tumor growth .
Tissue microarrays have shown the presence of PDGFRα in the stroma (46.7 % of 210tissues 
evaluated) of pancreat ic cancer in the tissues evaluated (data on file).  The link between PDGF 
and tumor -associated angiogenesis is supported by [CONTACT_853616] n by [CONTACT_20405], and 
overexpressio n was found to be correlated with microvascular den sity and poor survival in a 
large variet y of human cancers, including pancreatic cancer ( Fujimoto et al. 1998).
Blocking PDGFRα by  [CONTACT_853617], STS, with recent results showing improvement in OSand PFS.  The abilit y to inhibit 
PDGFRα signaling in pancreat ic cancer may represent an opportunit y to disrupt signaling in the 
tumor microenvironment in a manner that could potentially  enhance the ant itumor activity 
I5B-MC-JGDP(e)Clinical Protocol Page 29
LY3012207already obs erved with gemcitabine plus nab -paclitaxel, an established standardofcareregimen 
for the treatm ent of metastatic pancreat ic cancer.
5.4.1.Rationale for Amendment (a)
Amendment (a) u pdated the Phase 1b design to enroll pat ients in the Day s1, [ADDRESS_1188057], and begin enrollment in the Day s1 and 15 dosing cohorts if the Day s1, 8 and 15 cohort is 
not tolerable. In addition, the design was changed to add a cohort expansio n to ensure an 
appropriate number of patients (12 to 15 patient s) are evaluated for safet y in Phase 1b at the 
highest tol erated dose.
5.4.2.Rationale for Amendment (b)
Amendment (b) revised the definit ion of DLT based on Food and Drug Administration ( FDA)
feedback to include toxicit ies related to the combination of olaratum ab plus gemcitabine and 
nab-paclitaxel.
5.4.3.Rationale for Amendment (c)
Amendment (c) addresses several requests from FDA includinglanguage urging caut ion when 
administering nab -paclitaxel wit h CYP2C8 or CYP3A4 inhibitors or inducers as well as further 
details regarding the sample size just ification.
In addition, this amendment adjusts the study  entry criteria-related pri or therapi [INVESTIGATOR_014].  DLT 
wordingswere clarified to ensure that clinically non -significant AEs are not included in the DLT 
definition.  This amendment describes that a patient’s dose may  be re-escalated after a dose 
reduction. The schedule and timing of PROs in the fo llow-up periods (both l ong-term and short -
term) have been updated.  Plans for the Phase 2 interim analysis and the Internal Asse ssment 
Committee ( IAC)have been updated. In addition, several administrative items have been 
updated to provide clarit y or correct errors.
5.4.4.Rationale for Amendment (d)
Amendment D updates the protocol to include dose and schedule of olaratumab to be 
administered in the Phase 2 part ,based on the results of the Phase 1b part of study  JGDP. 
In Part 1b of Study JGDP, a total  of 22patients were enrolled and treated with olaratumab plus 
gemcitabine/nab -paclitaxel as of [ADDRESS_1188058] profile.  Both dose levels of 
olaratumab (i.e.15 mg/kg and 20 m g/kg olaratumab [N=3 and 19 patients, respectively] ) were 
tolerated in co mbination with gemcitabine/nab -paclitaxelwith one DLT reported at the 20 mg/kg 
olaratumab dose level (Grade 4 neutropenia lasting greater than 7 days ).  No maximum tolerated 
dose for olaratumab in combination with gemcitabine/nab -paclitaxel was ident ified.  AEs 
reported were consistent in nature and within the frequency range expected for chemotherapy  
with gemcitabine plus nab-paclitaxel or ol aratumab therapy .  Though the MTD of olaratumab 
was not re ached, a trend towards a higher number of early Grade ≥3 neutropenia and dose 
reductions in nab -paclitaxel and gemci tabine was noted am ong patients treated at the 20mg/kg 
I5B-MC-JGDP(e)Clinical Protocol Page 30
LY3012207dose level relative to the 15 mg/kg olaratumab dose level.  Therefore, considering safety and 
exposure-response analyses across olaratumab studies , the recommended dose for the 
randomized part of Study JGDP for ol aratumab in combinat ion with gemcitabine plus nab-
paclitaxel was determined as a 20 mg/kg olaratumab l oading dose on Days 1, 8, and 15 in 
Cycle1, followed by 15 m g/kg on Days 1, 8, and 15 in Cycles 2 -n.  This selected Phase 2 dose 
and schedule of olaratumab aims to maximize patients achieving concentrations above 
previously identified olaratumab serum levels associ ated with clinical activity, while also 
minimizing reductions/o missions of the standard-of- care chemotherapy backbone .  This decisio n 
was mutually agreed upon following discussio ns between the sponsor and the Study  JGDP 
Phase1b investigators. 
This amendment also formalizes a change from  an IAC (internal assessment committee) to an 
IDMC (independent data monitoring co mmittee) for th e Phase 2 part of the study  to enable 
monitoring of unblinded safet ydata by [CONTACT_853618]. This change is being made prior to any data being reviewed by [CONTACT_476994].  
In addition, clarifications to the inclusio n/exclusio n criteria # [1], [3], [5], [9], and [22];
olaratumab premedication ;and infusio n instructions in alignment w ith the recent invest igators 
brochure are provided.  S ome minor edi torial changes have been made throughout the protocol to 
improveclarity and pract icality of the protocol  and secure alignment with the intended study  
design.
5.4.5.Rationale for Amendment ( e)
Amendment (e)updates the protocol to include screening criteria for Immunoglobulin E (IgE)
antibodies against galactose-α-1-3-galactose (α-gal) and premedicat ion requirements to mit igate 
the risk for an observed rate of Grade ≥3 infusion -related reacti ons (IRRs) on Study  JGDP that 
was greater than the rate of 3.1% previously observed across the olaratumab program .  Based on 
data from  the Phase 1 and Phase 2 portion of Study  JGDP, Grade ≥3 IRRs wereobserved at an 
approximate rate between 5% and 10% of olaratumab- treated pati ents.
Infusion related reacti onsarea known A dverse Drug Reactionfor olaratumab, andthe rate of 
IRR is 12.5% (all grades) and 3.1% ( Grade ≥3). Grade ≥[ADDRESS_1188059] ic reaction is associated with elevated IgE 
antibody levels.  Across 8 studi es with olaratumab (401 evaluable olaratumab- treated pati ents), 
IgE antibody  levels greate r than the m anufacturer -specified ULN hada positive predict ive value 
of 75% (34.9% -96.8%) and a negative predict ive value of 99% (98.2% -99.9%) for Grade ≥3 
IRRs, with sensitivity of 75% (34.9% -96.8%) and specificit y of 99% (98.2% -99.9%). Two 
patients had Grade ≥3 IRR wi th an IgE antibody  level ≤ ULN (0.28 kU/L and <0.10 kU/L, 
respectively ).  Prior to this amendment, patient s in Study JGDPwere tested for pre -existing IgE 
antibody against α-galas pre-planned retrospective analysis. However,the results of these tests 
werenot availa ble prior to first dosing of o laratumab /placebo.  Pre-testing for elevated IgE 
antibody levels against -gal forall untreated patients as part of screening is being implemented 
as arisk mitigation strategy .
I5B-MC-JGDP(e)Clinical Protocol Page 31
LY3012207This amendment implements actions to mitigate the risk of increasedGrade ≥3 IRRsobserved in 
Study JGDP.  Specifically ,screening in the Phase 2 portion of the study  was modified to i nclude 
immuniogenicit y testing,and the inclusio n/exclusion criteria were upd ated to clarify  that patients 
with IgE anti-α-galantibody levelsgreater than the upper limit of normal will be excluded from  
this study. In addition, the required premedicat ion regimen prior to Cy cle 1 Day  1 of 
olaratumab/placebo was clarified to include: dexamethasone (or steroid equivalent) ; a histamine 
H1 antagonist ist (for example, di phenhydramine); and a h istamine H2 antagonist (for e xample, 
ranitidine).  
5.5.Justification for Olaratumab Dose
Olaratumab will be init ially dosed on Days 1, 8, and 15 to dose olaratumab coinciding with the 
dosing schedule of the gemcitabine and nab -paclitaxel backbone chemotherapyregimen.  In the 
event the Day 1, 8, and 15 dosing schedule is not tolerated, dosing of olaratumab on Day  1 and 
15 may be evaluate d to determine if less frequent dosing of o laratumab may improve the 
feasibility of the combinat ion.
The starting dose level of olaratum ab administered onthe Day 1, 8, and 15 schedule will be 
15mg/kg(Cohort 1) .  In monotherapy dose -escalation studies ,no DLTs were observed up to 
olaratumab doses of 20 mg/kg every other week and 16 mg/kg weekly for 4 weeks fo llowed by 2 
weeks off tre atment for observation.
In prior studies of olaratumab plus chemotherapi[INVESTIGATOR_014] (doxorubicin in STS [JGDG], paclitaxel plus 
carboplatin in non-small cell lung cancer [JGDB], mitoxantrone in prostate cancer [JGDD], and 
liposomal doxorubi cin in ovarian cancer [JGDA]), olara tumab was generally  well tolerated with 
manageable toxicit ies.  Some increase in hematological AEs (such as neutropenia) was noted 
over chemotherapy  alone.  In Studi es JGDG and JGDA, despi[INVESTIGATOR_853604].  In Study  JGDB, Grade ≥4 febrile  neutropenia was 3.0% on the olaratumab plus 
paclitaxel/carboplat in arm versus 0% on t he paclitaxel/carboplat in arm.
In several ongo ing studies, a Cycle 1 loading dose of 20 mg/kg has been safely administered in 
on Days 1 and 8 of Cycle 1 in combination wit h doxorubicin.  The exposures ant icipated fro m 
the starting dose of 15 mg/kg on Day  1, 8,and 15 would be ant icipated to be similar to those 
achieved for patients receiving the 20 -mg/kg loading dose on Days 1 and 8 of a 3 -week cycle.  
Based upon the increase in hematological AEs observed w henolaratumab was administered with 
previous chemotherapy  regimens, i t is anticipated that myelosuppressio n may be a key safety 
measure in determining the maximum tolerated dose of olaratumab wit h the combinat ion of 
gemcitabine plus nab -paclitaxel.  Weekly  assessment of hematol ogic parameters will provide 
close monitoring of this toxicity and aid in determining t he safety of this combinat ion.
The second dose level, 20 mg/kg (Cohort 2) , provides the opportunit y to achieve higher serum 
concentrations of olaratumab.   
 
 
CCI
I5B-MC-JGDP(e)Clinical Protocol Page 32
LY3012207 
 
 
In the event that the Day  1, 8, and 15 dosing schedule is not tolerated, an alternate dosing 
schedule with o laratumab administered on Day 1 and 15 may be explored.
For administration of olar atumab on the Day  1 and 15 schedule, t he starting dose is 20 mg/kg 
(Cohort 3).  This dose and schedule of olaratumab has been administered in prior studies (JGDA, 
in combination with liposomal doxorubicin in patients with ovarian cancer).  In addition, a 
loading dose of 20 mg/kg in Cycle 1 (Days 1 and 8 of a 21 -day cycle) has been safely
administered in several ongo ing studies (JGDJ, JGDI ,and JGDK) in co mbination with 
doxorubicin.  
 
After determinat ion of the MTD in the dose escalation portion of the study  and confirmat ion of 
the safety and tolerability of that dose in the cohort expansio n, a review of safety data, including 
the number and ty pe of DLTs, other safet y information , and relevant PK,will be conducted prior 
to proceeding to Phase 2.   The decisio n to proceed to Phase [ADDRESS_1188060] igators and Lilly clinical 
research personnel.
CCI
CCI
I5B-MC-JGDP(e)Clinical Protocol Page 33
LY30122076.Study Population
Prospective approval o f protocol deviations to recrui tment and enro llment criteria, also known as 
protocol waivers or exempt ions, is not permitted.
6.1.Inclusion Criteria
Patients are eligible to be included in the study  only if they meet all of the following criteria:
[1]have definit ive histological or cytological diagnosis of adenocarcinoma of the 
exocrine pancreas that is metastatic (i.e. Stage IV according to AJCC v8)and 
not amenable to resection wit h curative intent (Amin et al. 2017). The 
definitive diagnosis of metastatic pancreat ic adenocarcino ma will be made by 
[CONTACT_853619] .
Eligible patients must be patients for whom nab-paclitaxel -gemcitabine 
therapy is considered by [CONTACT_853620] .  
Patients with previous radical  surgery for pancreat ic cancer are eligible after 
progression is documented.
[2]if present, clinicallysignificant or symptomat ic amounts of ascites should be 
drained prior to Day  1
[3]have sufficient available material from an archived form alin-fixedparaffin-
embedded (FFPE) tumor tissue for biomarker-related studi es. If such tissue is 
not available, a newly obtained core or excisio nal biopsy of a tumor lesion 
must be performed in the Phase [ADDRESS_1188061] a second attempted biopsy, aft er consultation wit h the Lilly 
Medical representative. 
[4]The patient has measurable or nonmeasurable but evaluable disease as defined 
by [CONTACT_426076] (RECIST 1.1, 
Eisenhauer et al. 2009). Tumors within a previously  irradiated field will be 
designated as “nontarget” lesio ns unless progression is documented or a 
biopsy is obtained to confirm persistence at least 90 day s following 
completion of radiotherapy .
[5]have had no prior systemic treatmentfor metastatic di sease. Prior adjuvant or 
neo-adjuvant chem otherapy or radiochemotherapy(other than nab -paclitaxel) 
is allowed , if completed ≥3months prior to enrollment and no lingering 
toxicities are present .
[6] prior radiation therapy  for treatment of cancer is allowed to <25% of the bone 
marrow (Cristy and Eckerman 1987 ).  Patients must have recovered from the 
acute toxi c effects of their treatment prior to study  enrollment.
[7] have a performance status (PS) of 0 to 1 on t he Eastern Cooperative Oncology 
Group (ECOG) sc ale (Oken et al . 1982)
I5B-MC-JGDP(e)Clinical Protocol Page 34
LY3012207[8]Patients must have discont inued from previous treatments for cancer
(radiotherapy/major surgery, excl uding biopsy) 4 weeksprior to study  
treatment.
[9]have adequate organ funct ion, as defined below :
System Laboratory Value
Hematologic
ANC 1.5 × 109/L
Platelets 100 × 109/L
Platelet transfusions to meet eligibility reruirements are not 
allowed within 2 weeks prior to the baseline hematology 
profile.
Hemoglobin 9g/dL
Transfusions to increase the patient ’s hemoglobin level to 
9g/dLare not permitted within 2weeksprior to the baseline 
hematology profile.
Hepatic
Total bilirubin 1.5 × ULN   
ALT and AST 2.5 × ULN OR
5 × ULN if the liver has tumor involvement
Renal
Serum creatinine OR
Calculated creatinine clearance (see 
Appendix 6 )1.5 × ULN OR
60 mL/min
Coagulation
INR or PT Normalized ratio ≤1.5 × ULN or prothrombin time
≤1.5 × ULN
aPTT or PTT PTT or aPTT ≤1.5 × ULN if not receiving anticoagulation 
therapy.  For patients receiving anticoagulants, exceptions to 
these coagulation parameters, are allowed if they are within 
the intended or expected range for their therapeutic use.
For patients receiving anticoagulants, exceptions to these coagulation parameters areallowed if they are 
within the intended or expected range for their therapeutic use.  Patients must have no history of active 
bleeding (defined as within [ADDRESS_1188062] dose of study drug) or pathological condition that carries a high 
risk of bleeding (e .g., tumor involving major vessels or known esophageal varices) .
Abbreviations:  aPTT = activated partial thromboplastin time; ALT = alanine aminotransferase; 
ANC=absolute neutrophil count; AST = aspartate aminotransferase; PT = p rothrombin time; ULN = upper 
limit of normal.
[10]are at least 18 years old at the time of screening/rando mization
[11]If male, the patient is sterile (including vasectomy) or agrees to use an 
effective method of birth control .Refer to Appendix 1 for definitions of 
effective method of contraception and highly effective m ethod of 
contraception.
I5B-MC-JGDP(e)Clinical Protocol Page 35
LY3012207[12]If female:
ois not of childbearing potential due to surgical sterilizat ion confirmed by 
[CONTACT_9870]  (at least [ADDRESS_1188063] -surgical bilateral oophorectomy with or 
without hysterectomy  or tubal ligation) or menopause
ois of childbearing potential, has a negat ive serum or urine pregnancy  test 
within [ADDRESS_1188064] will be required.  Refer to Appendix 1 for definitions 
of effective method of contraception and highly effective method of 
contraception.
[13]have given written informed consent/assent prior to any study -specific 
procedures
[14] has a life expectancy  of at least 3 months in the opi[INVESTIGATOR_3078] n of the investigators .
6.2.Exclusion Criteria
Patients will be excluded from  the study  if they meet anyof the following criteria:
[15]have received first line treatment for metastatic pancreat ic cancer.
[16]have received prior treatment with nab-paclitaxel.
[17]have a serious conco mitant systemic disorder (for example, active infect ion 
including human immunodeficiency  virus, or cardiac di sease) or other 
condition that, in the opi[INVESTIGATOR_3078] n of the invest igator, wou ld compro mise the 
patient’s abilit y to adhere to the protocol
[18]have knowncentral nervous system  (CNS) m alignancy or m etastasis 
(screening not required)
[19]have current hem atologic malignancies, acute or chronic leukemia
[20]have participated within the last [ADDRESS_1188065] has a long 
half-life, 3 months or 5 half -lives (whichever is longer) should have passed.
[21]are women with a positive pregnancy test or who are lactating
[22]haveknown endocrine pancreat ic tumors or ampullary cancer
[23]are currently enrolled in a clinical trial invo lving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
[24] have known addi tional malignancy that is progressing or required act ive 
treatments within the past 1year
I5B-MC-JGDP(e)Clinical Protocol Page 36
LY3012207Note:  Parti cipants wi th basal cell carcino ma of the skin, squamous cell 
carcinoma of the skin, or carcino ma in situ (e.g., breast carcino ma, cervical 
cancer in situ) that have undergone potentially curative therapy  are not 
excluded.
[25]haveknown allergy to nab-paclitaxel,gemcitabine,or olaratumab (levels of 
IgE antibodi es against α-gal that are above the upper limit of normal) or any 
ingredient of olaratumab, nab-paclitaxel,or gemcitabineformulations.
6.3.Lifestyle Re strictions
This section is not applicable .
6.4.Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
re-screened.  Individuals may be re -screened a maximum of [ADDRESS_1188066] sign a new informed consent form (ICF)and will be assigned a new ident ification number.
Repeating of laboratory tests duri ng thescreening period , after a patient has not met requisite 
criteria,does not constitute re -screening. Screening laboratory  tests may not be repeated m ore 
than twice in order to meet eligibilit y during the screening period .
I5B-MC-JGDP(e)Clinical Protocol Page 37
LY30122077.Treatment s
7.1.Treatments Administered
TableJGDP.6shows the treatment regimens .  The dosing of nab -paclitaxel and gemci tabine will  
bethe same for all cohorts.  The dosing of olaratumab will vary  based upon cohorts in the 
Phase1b.  The Phase 2 dose and schedule of o laratumab/placebo has been selected based upon 
results of the Phase 1b (Section 5.4.4).
TableJGDP.6. Treatment Regimens
Phase Drug Route DoseSchedule
q 28-day cycleApproximate 
Infusion
Duration
Phase 1b
Cohorts 
1 and 2OlaratumabaI.V. 15, 20 mg/kg D1, D8, D15 60 min
nab-paclitaxel I.V. 125 mg/m2D1, D8, D15 30 -40 min
Gemcitabine I.V. 1000 mg/m2D1, D8, D15 30 min
Cohorts 
3 and 4OlaratumabaI.V. 20, 25 mg/kg D1, D15 60 min
nab-paclitaxel I.V. 125 mg/m2D1, D8, D15 30 -40 min
Gemcitabine I.V. 1000 mg/m2D1, D8, D15 30 min
Phase 2 olaratumab /placeboaI.V.
I.V.Cycle 1:20 mg/kg
Cycle 2-n:15 mg/kgD1, D8, D15
D1, D8, D1560 min
60 min
nab-paclitaxel I.V. 125 mg/m2D1,D8, D15 30 -40 min
gemcitabine I.V. 1000 mg/m2D1, D8, D15 30 min
Abbreviations:  D =day; I.V.= intravenous; q=every.
aFor mandatory premedication requirements please see Section 7.1.1.
Patients will receive study  treatments in the following order: olaratumab fo llowed by 
[CONTACT_131703]-paclitaxel followed by [CONTACT_35421].  Omissio n or discontinuation of one component of the 
regimen m ay change that sequence, but remaining treatments should st ill be given in the same 
relative order. 
Olaratumab will be administered as an approximately 60minute I.V.infusion on Days 1, 8, and 
15 of a 28- day cycle at the doses shown in TableJGDP.6.  In certain instances, longer infusio n 
times may  be allowed; refer to Pharmacy  Manual for m ore informati on.  
Patients are requi red to be monitored for [ADDRESS_1188067] two 
treatment cycles for signs or symptom s of IRRs; see Secti on [IP_ADDRESS].1 for full description o f 
required olaratumab monitoring period.  Patients should complete the required mo nitoring peri od 
prior to the start of any other study  treatment (gemci tabine or nab -paclitaxel) administration.
7.1.1.Premedication
All premedication adminis tered must be adequately  documented in the electronic case report 
form (eCRF).
I5B-MC-JGDP(e)Clinical Protocol Page 38
LY30122077.1.1.1. Olaratumab/Placebo
Infusion-related reacti ons, including Grade ≥[ADDRESS_1188068] been observed with olaratumab . To 
date, all Grade ≥[ADDRESS_1188069] included flushing, 
shortness of breath, bronchospasm, fever/chills, and in severe cases have manifested as severe 
hypotension, anaphylact ic shock, or cardiac arrest. 
The following prem edications need to be administered prior to olaratumab/placebo infusio ns in 
Study JGDP.Additional premedication may be provided at the invest igator’s discret ion.
Premedication in Cycle 1:
Premedication is mandatory for allpatients during Cy cle 1 prior to each dose of 
olaratumab/placebo. Premedicate all pat ients with the following (or equivalent )
medications 30-60 minutes prior to olaratumab /placebo dosing on Days 1, 8, and 15 of 
Cycle 1:
oHistamine H1 antagoni st (for example, diphenhydramine)
oDexamethasone intravenously
oHistamine H2 antagon ist (for example, ranitidine)
Premedication in Cycles 2-n:
For subsequent cy cles, prem edication with a histamine H1 antagonist (for example, 
diphenhydramine) i s recommended prior to each dose of olaratumab/placebo.
In case of prior Grade  1 or 2 IRR to olaratumab, premedication is mandatory prior to
subsequent infusio ns with olaratumab.After a Grade 1 or 2 IRR, patients should be 
premedicated wi th the following (or equivalent) medicat ions prior to all subsequent 
olaratumab/placebo infusio ns:
oHistamine H1 antagoni st (for example, diphenhydramine)
oGlucocorticoid (for example, dexamethaso ne) intravenously
oAcetaminophen orally  
Treatment guidelines for olaratumab IRRs are described in TableJGDP.7.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188070] medical practice; may include, but 
is not limited to:
Antihistamines (for example, diphenhydramine 
HCl)
Steroids (for example, dexamethasone)
Acetaminophen
Oxygen
After recover y, the infusion rate should be decreased to 
50% for the duration of the infusion.Patients should be premedicated 
with antihistamines, steroids, 
acetaminophen, etc., as 
appropriate.
Grades 3 o r 4 Stop infusion.
Administer immediate treatment. May include, but is not 
limited to:
Epi[INVESTIGATOR_238]
Bronchodilators and/or glucocorticoids for 
symptomatic b ronchospasm
I.V.fluids and/or pressors for hypotension
Treatment with olaratumab should be immediately 
and permanently discontinued.No subsequent dosing
All attempts should be made to obtain an anti -olaratumab antibody and olaratumab PK blood samples as 
close to the onset of the event as possible, at the resolution of the event, and 30 days (±3 days) following the 
event.The procedure for sample collection and handling is described in a separate procedural man ual.
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug administration.
Abbreviations: HCl = hydrochloride; I .V.= intravenous; NCI  CTCAE = National Cancer Institute Common 
Terminology Criteria for Adverse Events.
[IP_ADDRESS]. Nab-paclitaxel
Premedication to prevent hy persensitivity reactions is generally  not needed pri or to the 
administration of nab -paclitaxel.  Severe and so metimes fatal  hypersensit ivity reactions, 
including anaphylact ic reactions, have been reported (Abraxane®Prescribing Information2015) .  
Patients who experience a severe hypersensit ivity reaction to nab-paclitaxel should not be re -
challenged with it.
[IP_ADDRESS]. Gemcitabine
Prophylactic ant iemetics may be routinely administered to patients during the course of the study  
as per the decisio n of the invest igator.  Additionally, premedicat ion for gemcitabine may be 
administered according to inst itutional guidelines an d/or clinical practice.   
Sites should consult the manufacturer’s instructions for gemcitabine for complete prescribing 
information (including warnings, precautions, contraindicat ions, and adverse reactions) and 
follow institutional procedures for the admi nistration of gemcitabine.
I5B-MC-JGDP(e)Clinical Protocol Page 40
LY30122077.1.1.4. Granulocyte -Colony Stimulating Factors
Growth factors and erythropoiet in are allowed per American Societ y of Clinical Oncology or
National Com prehensive Cancer Network guidelines. Short-acting G-CSF(for example, 
filgrastim )should be administered at least [ADDRESS_1188071] 24 hours prior to the next dose of chemotherapy . Longer-acting G-CSF 
(for example, pegfilgrastim) should be given at l east [ADDRESS_1188072] dose of chemotherapy 
in the cycle .  
Duration of uncomplicated neutropeni a before init iation of G- CSF treatm ent is left to the 
investigator’s discretion. Transfusio ns are permitted. No other therapy, including routine use o f 
GFs or experimental  medications (for example, immunotherapy or other unapproved 
medication),will be permitted while the patients are on the study .
7.1.2.Investigator Responsibilities
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the drugs and planned duration of each individual’s 
treatmentto the study site personnel, the patient, and/or the patient’s legal 
representative
verifying that ins tructions are fo llowed properly
maintaining accurate records o f study treatment dispensing and collect ion
following the protocol at all times
at the end of the study ,returning all unused medication to Lilly or its designee, 
unless Lilly  and sites have agreed all  unused m edication is to be destroy ed by [CONTACT_39722], as allowed by [CONTACT_1769]
contact[CONTACT_853621] a subject to ensure 
enrollment availabilit y in the Phase 1b. Refer to Section7.2.1.
maintaining contact [CONTACT_853622] ( CRP)to discuss 
DLTs and potential dose changes due to DLTs
The pharmacy manual contains informat ion about preparation and administration of study  
treatment.Section 7.1.1contains information about any required or suggested premedicat ion.
7.1.3.Packaging and Labelling
Olaratumab/placebo ,gemcitabine , and nab-Paclitaxelwill be provi ded by [CONTACT_11007].  Olaratumab 
drug product is supplied in single -use, 50-mL nominal volume, [LOCATION_002] Pharmacopeia
Type I glass vials. Each vial contains 500 mg of olaratumab at a concentration of 10 mg/mL, in 
a sterile,preservative-free solution. Each vial is stoppered with a coated butyl rubber latex- free 
plug stopper and sealed with an aluminum seal and a flip- off cap.
In the event of regional restrict ions or supply limit ations, commercially available gemcitabine 
andnab-Paclitaxel may be purchased by  [CONTACT_8979].  Clinical trial materials will be labeled 
according to the country’s regulatory  requirements.
I5B-MC-JGDP(e)Clinical Protocol Page 41
LY30122077.1.4.Dose-Limiting Toxicity Determination (Phase 1b)
Myelosuppressi on is expected with the nab-paclitaxel and gemci tabine regimen and can lead to 
complications such as fever and neutropenia, sepsis, infect ion, or bleeding.  These adverse events 
aregenerally considered DLT -level toxicit ies and thus can confound DLT determination in the 
setting of co mbination with olaratumab.  The criteria listed below will be used to determine the 
dose of olaratumab that can be added to nab -paclitaxel and gemcitabine without causing a 
significant increase in toxicit y over that expected with nab -paclitaxel -gemcitabine alone.
A DLT is define d as events such as the fo llowing, graded according to the NCI -CTCAE v ersion
4.03, when the event occurs within Cycle 1, and is considered to be related to olaratumabin 
combination with nab-paclitaxelplus gemci tabineby [CONTACT_853623]:
Any febrile neutropenia
Grade 4 thrombocy topenia, or Grade 3 thrombocy topenia complicated by [CONTACT_853624]
Grade [ADDRESS_1188073] ing 7 days or longer
nonhematologic Grade ≥3 toxicity, except for 
-toxicities such as nausea ,vomiting,transient electroly te abnorm alities,diarrhea which 
can be controlled wit h optimal medical management within 48 hours;
-non-clinically significant, treatable, or reversible laboratory  abnormalities including
liver funct ion tests, uric acid, e lectrolytes, etc.
Any other significant toxicit y deemed by  [CONTACT_853625] -limiting (e.g., any toxicity that is possibly related to the 
study medication that requires the withdrawal o f the patient from the study during Cycle 
1).
The MTD i s defined as the highest olaratumab dose level at which no more than 33% of patients 
experience a DLT during Cycle 1.
Phase 1b
In addition to the DLT assessment period in Cycle 1, safet y data beyond Cycle [ADDRESS_1188074] of care treatment regimen and PK may be taken into consideration in 
selecting the dose recommended for use in the Phase 2 portion of the study .
Note:  Infusion-related reacti onswill not be counted as DLTs, as they occur independent of dose 
level.
7.2.Method of Treatment Assignment
The following treatments will be administered to enrolled patients in this study  every 4weeks
(28-daycycle).
The Interactive Web Response System (IWRS), which is web -based and access ible [ADDRESS_1188075] udy.  The IWRS registration 
I5B-MC-JGDP(e)Clinical Protocol Page 42
LY3012207consists of assigning the patient a unique study  identificati on number.  Once the patient is 
registered through the IWRS, he/she is considered to be enro lled in the study .
7.2.1.Phase 1b
Investigators are required to contact [CONTACT_853626] a patient 
in Phase 1b. Once enro llment availabilit y is confirmed, sites may  proceed wi th screening of 
patient and registration into Interactive Web Response Sy stem (IWRS), whi ch is web -based and 
accessible 24 hours a day.  No dose escalat ions (that is, to the next cohort) can occur without 
prior discussion and agreement with th e responsible Lilly CRP or clinical research scient ist.
Phase 1b pat ients will not be eligible to participate in the Phase 2portion of the study.
7.2.2.Phase2
Patients who m eet all criteria for enrollment will be randomly assigned via IWRS to receive 
either olaratumabplus nab-paclitaxel and gemci tabine(Treatment Arm)or placeboplus nab-
paclitaxel and gemcitabine (Control Arm).  Approximately 162patients will be rando mized in a 
1:1 ratio.
Randomization will be stratified into 4 groups, one for each combinat ion of the following 2 
baseline factors:
Age group (<70 y ears versus ≥70 years)
Prior adjuvant/neo -adjuvant therapy(yes versus no)
Once the pat ient is registered through the IWRS, he/she is considered to be enro lled in the study .  
After rando mization, patients shoul d receive thei r first dose of treatment within 72 hours (3 day s) 
whenever possible.   Up to [ADDRESS_1188076] dose of treatment will be permitted due
to holidays, weekends, bad weather, or other unforeseen circumstances and will not count as a
protocol deviation.
7.2.3.Selection and Timing of Doses
A cycle is defined as an interval of 28 days.  A delay  of a cycle due to holiday, weekend, bad 
weather, or other unforeseen circumstances will be permitted for a maximum of 3days and not 
counted as a protocol deviat ion.
The actual  doses of olaratumab administered will be determined by [CONTACT_95850] ’s body 
weight inkilograms at the beginning of each cycle.  If the patient’s weight does not fluctuate by  
[CONTACT_726] 10% from the weight used to cal culate the pri or dose, the dose will not need to be 
recalculated.  A 5% variance in the calculated total dose will be allow ed for ease of dose 
administration.
The actual  doses of n ab-paclitaxel and gemcitabineadministered will be determined based on 
estimation ofbody surface area (BSA) in m2on Day 1 of each28-day cycle.  If the patient’s 
weight does not fluctuate by  [CONTACT_726] 10% from the weight used to calculate the prior dose, 
the BSA will not need to be recalculated, unless deemed clinically meaningful (recalculat ion 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188077] ice/standard).  A 5% variance in the calculated total 
dose will be allowed for ease of dose administration.
A patient may continue to receive study treatment until he or she meets one or more of the 
specified reasons for discontinuation (as described in Section 8).
7.3.Blinding
The Phase 1b portio n of this study  is open-label.
Phase [ADDRESS_1188078] igator has the sole responsibilit y for determining if unblinding 
of a patient’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the investigator decides that unblinding is 
warranted, the investigator should make every effo rt to contact [CONTACT_853627] 
a patient’s treatm ent assignment unl ess this coul d delay emergency treatment of the patient.  If a 
patient’s treatment assignment is unblinded, Lillymust be notified immediately.
Emergency  unblinding for AEs mustbe performed through the IWRS. Allactionsresulting in an 
unblinding event are recorded and reported by  [CONTACT_720685].
7.3.2.Inadvertent Unblinding
Every effort will be m ade to blind both the patient and the invest igator to the ident ity of the 
treatment, but the inadvertent unblinding of a patient may occur.  If an invest igator, site 
personnel, or patient is inadvertent ly unblinded, the unblinding wil l not be sufficient cause for 
the patient to be discontinued from study  treatment or excluded fro m study analyses.
Additionally, there may be ethical reasons for the patient to remain on the study  treatment.  In 
the event of unblinding, the invest igator mu st obtain specific approval fro m a Lilly CRP for the 
patient to continue in the study .
7.4.Dosage Modification
Guidance for dose adjust ment, delays, and discont inuationof blinded study  drug
(olaratuma/pl acebo), gemcitabine and nab -paclitaxel due to hematologi cal and 
non-hematological toxicities are presented in Sections 7.4.2,7.4.3,and 7.4.4, respectively.  
Gemcitabine and nab -paclitaxel are intended to be admin istered in accordance with standard-of-
care in this study  and dose modifications should follow the l ocal labels.Investigators will 
interpret and docum ent whether or not an AE has a reasonable possibilit y of being related to each 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188079] study  drug(s)doses. 
To begin dosing at each cy cle, the following criteria must be fulfilled:
Absolute neutrophil count ( ANC)≥1.5 × 103cells/µL ( ≥1500 cells/µL; ≥1.5 × 109/L)
Platelets ≥100 × 103cells/µL ( ≥100,000 cells/µL ; 100 x 109/L)
Total bilirubin ≤1.5 ×upper limit of normal ( ULN)for Cycle 1.
For subsequent cycles, monitor and administer as per standard of care with dose 
adjustment based on individual tolerance.
Aspartate aminotransferase ( AST)and alanine aminotransferase ( ALT) ≤2.5 ×ULN, or 
≤5 ×ULN if the transaminase elevat ion is due to liver metastases
Nonhematologic toxicit y must beCTCAE < Grade [ADDRESS_1188080] igator (such as 
alopecia) or is a laboratory abnormality that is manageable by [CONTACT_141798] 
(such as asymptomat ic electrolyte distur bances).  TableJGDP.11provides addit ional 
guidance for non -hematological toxicities of peripheral neuropathy , cutaneous toxicit y 
and mucosit is or diarrhea.
In the Phase 1b portion of the study , doses of ol aratumab and/or nab-paclitaxel or gemcitabine 
may be delayed, omitted, or reduced if the pat ient experiences an AE or a DLT -equivalent 
toxicity.
In the Phase [ADDRESS_1188081] igators will be blinded to treatment assignment (ol aratumab versus 
placebo) and shoul d adjust dosing of ol aratumab/placebo as if all pat ients are receiving 
olaratumab.
In the event of an alteration in olaratumab/placebo dose due to an olara tumab/placebo-related 
toxicity, gemcitabine or nab -paclitaxelneed not be al tered, and the planned gemcitabine or nab-
paclitaxel schedule shoul d be maintained.   Similarly, o laratumab /placebotherapy neednot be 
altered for either gemcitabine -or nab-paclitaxel-related toxici ty.
Omission or discontinuation of [ADDRESS_1188082] ment of one of the 
chemotherapy agents and not the other is permissible.   
I5B-MC-JGDP(e)Clinical Protocol Page 45
LY3012207Dose level reductions for nab-paclitaxel and gemcitabine are shown in TableJGDP.8.
TableJGDP.8. Dosing and Dose Reductions for Nab -paclitaxel and Gemcitabine
Nab-paclitaxel
(mg/m2)Gemcitabine
(mg/m2)
Starting Dose 125 1000
1stDose Reduction 100 800
2ndDose Reduction 75 600
TableJGDP.9summarize s dosing and dose reduction for olaratumab.
TableJGDP.9. Dosing and Dose Reductions for Olaratumab
Starting Dose (mg/kg) 15 20 25
1stDose Reduction (mg/kg) 12 15 20
2ndDose Reduction (mg/kg) 10 12 15
In the Phase 2 portion, patients will be started on a dose of 20 mg/kg in Cycle 1.  In the event a 
patients toxicity in Cycle 1 requi res an olaratumab dose reducti on,the patient may start Cy cle 2 
at the dose of 15 mg/kg olaratumab ,provided the toxi city necessitating dose reducti on has
adaequately resolved.
If a patient at the lowest dose level experiences toxicit y that would necessitate additional dose 
reductions, the patient shoul d discontinue that treatment .
Patients whoundergo a dose reduction may be re -escalated at the discret ion of the investigator 
once the toxicit y requiring dose reduction has returned to Grade ≤1or baseline .  
In the case of recurrent, pers istent toxicity, the investi gator shoul d consider perm anent dose 
reduction.  
7.4.2.Dose Modifications
[IP_ADDRESS]. Hematological Toxicites
General guidelines for dose modificationsfor hematologic toxicit ies are shown in
TableJGDP.10.
Olaratumab has been safely  administered wi thout any DLTsor significant myelo suppressive 
toxicity in monotherapy  studies.  In studi es with cytotoxic chemotherapi[INVESTIGATOR_014], ol aratumab has 
shown some increase in myelosuppressive toxicit ies; however, these toxicit ies are principally 
driven by [CONTACT_853628] o f the backbone chemotherapy.  In addit ion, exposure -response analysis of 
the Study JGDG dem onstrated the importance of achieving and maintaining o laratumab serum 
concentrations in a potentially therapeut ic range(see also Section 5.5).  For these reasons, 
hematological toxicity management will focus on dose modificat ion of gemcitabine and nab -
paclitaxel per label guidelines, and not by  [CONTACT_853629] (TableJGDP.10).  In the 
case of toxicit y related to myelosuppressio n and its complicat ions, the relat ive roles of 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188083] igator may deem it appropriate to reduce or modify o laratumab. 
TableJGDP.10. Dose Recommended and Modifications for Neutropenia and/or 
Thrombocytopenia within a Cycle
Cycle 
DayANCb
(cells/mm3)Platelet Count
(cells/mm3)nab-Paclitaxel /
Gemcitabine Dose Olaratumab Dose
Day 1<1500 OR<100,000 Delay dosing until counts 
are above indicated levelDelay dosing until counts 
are above indicated level
Day 8500 to <1000 OR50,000 to <75,000 Reduce 1 dose level Administer, n o dose 
reductiona
<500 OR<50,000 Withhold doses Withhold dose
Day 15:  if Day  8 doses were reduced or given without modification :
Day [ZIP_CODE] to <1000 OR50,000 to <75,000 Reduce 1 dose level from 
the dose level 
administered on Day 8Administer, n o dose 
reductiona
<500 OR<50,000 Withhold doses Withhold dose
Day 15:  if Day  8 doses were withheld:
Day 15≥1000 OR≥75,000 Reduce 1 dose level from 
Day 1 doseAdminister, no dose 
reduction
500 to <1000 OR50,000 to <75,000 Reduce 2 dose levels 
from Day 1 dose Administer, no dose 
reduction
<500 OR<50,000 Withhold doses Withhold dose
Any 
DayFebrile 
neutropenia- - Withhold doses until fever resolves and
ANC ≥1500 cell/mm3; resume dosing with a 1 dose 
level reduction
Abbreviations:  ANC = absolute neutrophil count; G-CSF = granulocyte colony -stimulating factor; 
Gem=gemcitabine; nab -P = nab-paclitaxel.
aAt the investigator’s discretion .
bNote that additional guidance for recommended dose delay/modifications for febrile neutropenia is shown in 
TableJGDP.11.
[IP_ADDRESS]. Non-Hematological Toxicities
TableJGDP.11shows general guidelines for dose modif ications due to non -hematological 
toxicities of study  drugs. 
For olaratumab IRRs, see Secti on7.[IP_ADDRESS].  For IRRs to nab -paclitaxel see Sect ion [IP_ADDRESS].3.
I5B-MC-JGDP(e)Clinical Protocol Page 47
LY3012207TableJGDP.11. Guidelines for Dose Modif ications due to Non-Hematological Study 
Drugs-RelatedToxicities
Toxicity Nab-paclitaxel Gemcitabine Olaratumab
Peripheral neuropathy
Grade ≥3Withhold until improves to 
≤Grade 1;resume dosing 
with a 1 dose level reduction 
from prio r doseNo dose reduction No dose reductiona
Cutaneous toxicity
Grade 2 or 3Reduce to next lower dose level; discontinue 
treatment if toxicity persistsNo dose reductiona
Grade 3 mucositis or 
diarrhea Withhold dosing until improves to ≤Grade 1;
resume at next lower dose level .Investigator’s discretion
Other Non –hematological Toxicity (except IRR to olaratumab)c
Persistent or recurrent 
Grade [ADDRESS_1188084] supportive 
careInvestigator discretion Investigator discretion
Grade 3 or 4 Withhold either one or both drugs as clinically 
indicatedb.  Then resume treatment at the next lower 
dose level Withhold until toxicity is ≤Grade 1 
or has returned to pretreatment 
baselinea,b; If toxicity recursor is 
Grade 4,treatment may resume at 
a reduced dose. If toxicity 
Grade4 recurs, discontinue 
olaratumab treatment .
Abbreviation:  ANC = absolute neutrophil count.
aDoseadjustments are allowed at discreti on of investigator fortoxicities deemed related to olaratumab/placebo.
bExcept toxicities that can be adaequately controlled with supportive treatment such as asymptomatic electrolyte 
disturbances, hyperlipi[INVESTIGATOR_035], skin rash, nausea, or vomiting .
cPlease see also specific discontinuation criteria for olaratumab ( Section [IP_ADDRESS]), gemcitabine (Section [IP_ADDRESS]), 
and nab-paclitaxel (Section7.4.4.2).  
7.4.3.Dose Delays
Treatment may be delayed for up to [ADDRESS_1188085] be discont inued from study treatmentunless the 
investigator, in consultat ion with the Lilly CRP/CRS, agree that it is in the best interest of the 
patient to continue treatment.  
Delays for nab -paclitaxel due to peri pheral neuropathy  are allowed to last longer than 28 days for
toxicity to resolve (m edian durati on of delay/resolution of AE to Grade ≤[ADDRESS_1188086] study  of gemcitabine plus nab-paclitaxel [ Von Hoff et al. 2013]).  Gemcitabine and 
olaratumab/placebo should be dosed on the planned schedule during delays for nab -paclitaxel-
related peripheral neuropathy .
If one (or more) study  drugs will be withheld(omitted), Day [ADDRESS_1188087] dose of any study  drug in that cy cle.  If  one (or more) study drugs will be withheld 
(omitted), the regular dosing intervalfor the non-affected study  drug(s) should try  to be 
maintained within or between cy cles according to the planned treatment schedule ( Section 7.1).  
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188088] ments to planned dosing may  be allowed upon consul tation with the 
Sponsor(for instance if all study treatment on day 15needs to be withho ld/omitted that week 
may beco me the week of rest and the next dose (if counts and chemistries permit) Day 1 of a 
new cycle) .  
7.4.4.Dosing Discontinuation
[IP_ADDRESS]. Gemcitabine
Pulmonary toxicity has been reported with the use of gemcitabine. In cases of severe lung
toxicity, gemcitabine therapy  should be discont inued immediately and appropriate supportive
care measures instituted.
Gemcitabine shoul d be perm anently discont inued for any of the fo llowing:
unexplained new or worsening dyspnea or evidence of severe pulmo nary toxicity
severe hepatic toxicit y
Hemolytic Uremic Syndrome or severe renal impairment
Capi[INVESTIGATOR_92306]
posterior reversible encephalopathy  syndrom e
[IP_ADDRESS]. Nab-paclitaxel
[IP_ADDRESS].1. Hepatic Impairment
Exposure and toxicit y of paclitaxel can be increased with hepat ic impairment oradministration 
of nab-paclitaxel in patients.  Do not administer nab -paclitaxel to pati ents with total bilirubin 
>5x ULN and/or AST > 10x ULN.
[IP_ADDRESS].2. Sepsis
Sepsis, wi th or without neutropenia, has been reported with the use of nab -paclitaxel in 
combination with gemcitabine. Biliary obstructi on or presence of biliary  stent were risk factors 
for severe or fatal sepsis. If a patient becom es febrile (regardless of ANC) ,initiate treatm ent 
with broad-spectrum ant ibiotics. For febrile neutropenia, interrupt nab-paclitaxeland 
gemcitabine until  fever resolves and ANC ≥ 1500, then resume treatment at reduced dose levels 
(see TableJGDP.11).
[IP_ADDRESS].3. Pneumonitis
Pneumonitis, including so me cases that were fatal, has been reported in patients receiving 
nab-paclitaxel in combinat ion withgemcitabine. Monitor patients for s igns and sympto ms of 
pneumonitis and interrupt nab-paclitaxeland gemci tabine during evaluat ionof suspected 
pneumonitis. After ruling out infect ious etiology and upon m aking a di agnosis of pneumo nitis, 
permanently discont inuetreatment with nab-paclitaxeland gemci tabine.
I5B-MC-JGDP(e)Clinical Protocol Page 49
LY30122077.[IP_ADDRESS]. Infusion -related Reactions/Hypersensitivity Reactions
Severe and so metimes fatal hypersensit ivity reactions, including anaphylact ic reactions, have 
been reported in patients receiving nab- paclitaxel. Patients who experience a severe 
hypersensit ivity reaction to nab-paclitaxelshould not be rechallenged wit h this drug.
[IP_ADDRESS]. Olaratumab
For non-hematological toxicities, refer to TableJGDP.11.
[IP_ADDRESS].1. Olaratumab Infusion -Related Reactions
Olaratumab should beimmediate lyand permanentlydiscontinuedfor Grade 3 or 4 IRR. For 
olaratumab IRR treatm ent guidelines see TableJGDP.7. 
Due the observed rate of Grade ≥3 IRRs in the Phase 1 and Phase 2 portions of Study JGDP that 
was greater than the rate of 3.1% previously observed across the olaratumab program , testing for 
IgE anti-α-gal antibodies mustbe performed as part of screening, and pat ient with antibody 
levels >ULN should be excluded.
Patients treated with olaratumab (olaratumab/placebo in the Phase 2 portion of the study )should 
be closely mo nitored for si gns and symptom s indicative of a hype rsensitivity/infusion-related
reaction from the start of the infusio n until at least 1 hour after the end of the infusio n,in an area 
where emergency medical resuscitat ion equipment and other agents (epi[INVESTIGATOR_238], predniso lone 
or equivalents, etc .) are available.  No other study  treatment (gemcitabine and/or nab -paclitaxel) 
should be administered during the observation period (prem edications for gem citabine and/or 
nab-paclitaxel are all owed to be administered during the observation period). 
If there is no e vidence of an IRR in the first [ADDRESS_1188089] ituted for a minimum o f 2 cycles.  The reins tituted 
observation period may be suspended after 2 cy cles if the pat ient shows no further signs or 
symptoms of an IRR .  If a patient experiences a nIRR, all attempts should be made to obtain an 
anti-olaratumab antibody and olaratumab PK blood samples as close to the onset of the event as 
possible, at the resolut ion of the event, and 30 day s (±3 days) following the event (See Appendix 
4and Section 9.5).
Signs and symptom s of IRRsmay vary in different pati ent populationsand include rigors/trem or, 
back pain/spasms, chills, flushing, dyspne a, pruritus or rash (without urticaria), fever, headache, 
body aches, abdominal pain, nausea, vo miting, and blurred visio n. In severe cases, symptoms 
have included wheezing, bronchos pasm, hypoxia, chest pain and/or tightness, supraventricular 
tachycardia, hypotensi on, and paresthesia.
The Lilly medical m onitor should be contact[CONTACT_853630].
I5B-MC-JGDP(e)Clinical Protocol Page 50
LY30122077.5.Preparation/Handling/Storage/Accounta bility
Refer to the IBor Pharmacy Manual for detailed storage informat ion of olaratumab and 
gemcitabine.  Invest igators should consult the approved nab -paclitaxel package insert for 
complete storage and stabilit y information.
It is the responsibilit y of the investigator or designee to ensure that a current record of 
investigat ional product disposit ion is maintained at each study  site where invest igational 
products are inventoried and disposed.  Records or logs must comply with applicable regulations 
and guidelines.
7.6.Treatment Compliance
The study  medication,which is administered intravenously , will be administered only at the 
investigat ional sites by [CONTACT_853631].  As a result, treatment compliance is 
ensured.  The treatment administ ration data are recorded in the patient’s medical record and 
eCRF.
7.7.Concomitant Therapy
Premedication guidelines are described in Section 7.1.1.
Patients may receive full  supportive care therapi[INVESTIGATOR_853605], including 
antiemetic treatment as per inst itutional guidelines. At each visit, appropriate documentation of 
all forms of premedicat ion, supportive care, and conco mitant medications must be captured on 
the study eCRF.
Concomitant medicat ions and supportive care must also be documented unt il [ADDRESS_1188090]. No other chemotherapy, immunotherapy, radiat ion therapy, 
surgery for cancer, or exp erimental  medications will be permitted while the pati ents are on study 
treatment orduring short -term follow-upperiod. Any disease progression requiring other forms 
of specific ant itumor therapy  will be cause for discontinuat ion from the study .
7.7.1.Other Concomitant Medication (CYP2C8 and CYP3A4 Inhibitors 
or Inducers)
The metabolism of paclitaxel is catalyzed by [CONTACT_097]2C8 and CYP3A4.  In the absence of formal 
clinical drug interaction studies, caution should be exercised when administering nab -paclitaxel 
concomitantly with medicines known to inhibit (e.g., ketoconazole and other imidazo le 
antifungals, ery thromycin, fluoxet ine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, 
and nelfinavir) or induce (e.g., rifampi[INVESTIGATOR_2513], carbamazepi[INVESTIGATOR_050], phenyto in, efavirenz, and nevirapi[INVESTIGATOR_050]) 
either CYP2C8 or CYP3A4.
7.7.2.Supportive Care
Patients will receive supportive care as judged by  [CONTACT_24018].  If it is unclear 
whether a therapy  should be regarded as supportive care, the invest igator should consult the Lill y 
CRP.  Use of any  supportive care therapy  must be captured on the eCRFs.
I5B-MC-JGDP(e)Clinical Protocol Page 51
LY30122077.7.2.1. Colony Stimulating Factors
Refer to Section [IP_ADDRESS].
[IP_ADDRESS]. Transfusion of Blood Product
Transfusio ns of red blood cells, platelets, or other blood products are permitted at the 
investigator’s discret ion, but may not be used to meet hematologic crite ria for inclusion in the 
study (refer to Secti on6.1, Inclusion Criterion [9]).
[IP_ADDRESS]. Antiemetic Therapy
Both prophylactic and symptom -directed ant iemetictherapi[INVESTIGATOR_853606] h institutional guidelines (when existent) and/or at investigator’s 
discretion.
7.7.3.Prohibited Therapie s
Additional concurrent chemotherapy , radiation therapy , biologic response m odifiers, or other
investigat ional or approved anticancer agents may  not be administered to patients on this study .  
Palliative radiation or surgery  to symptom atic sites of disease will not be permitted while on 
study.
7.8.Treatment after the End of the Study
Study completion will occur when the primaryanalysis o f OShas been completed. Investigators
will continue to fo llow the Schedule of Act ivities (Section 2) for all patients until notified by 
[CONTACT_853632].
Refer to Section 7.3for unblinding that occurs after study  completion.
7.8.1.Continued Access
After the finalanalysis of OShas been conducted, patients who are still on study treatmentat the 
time of study  completion may continue to receive study treatment if they are experiencing 
clinical benefit and no undue risks. Placebo will no l onger be administered, and crossover will 
not be permitted. The continued access period (seeFigure JGDP. 3) will apply to this study  only 
if at least 1 pati ent is still on study treatment when study  completion occurs.  Lilly will notify 
investigators when the continued access period begins.
I5B-MC-JGDP(e)Clinical Protocol Page 52
LY3012207Figure JGDP. 3. Continued access diagram.
The patient ’s continued access to study treatment will end when a criterion for discontinuation is 
met (Section 8).  Continued access fo llow-up will begin the day  after the pati ent and the 
investigator agree to discont inue study  treatmentand lastsapproximately  30 (±7) day s.
Follow-up procedures will be performed asshown in the Cont inued Access schedule of a ctivities 
in TableJGDP.4.
Patients who are in short -term follow-up when the continued access period begins will  continue 
in short-term follow-up until the 30-day short-term follow-up visit is co mpleted.  Long -term 
follow-up does not apply.
Patients who are in long -term follow-up when the continued access period begins will be 
discontinued fro m long-term follow-up.Study Treatment Period
aLilly will notify sites when the continued access period begins and ends . 
bFinal analysis of overall survival.  Lilly will notify sites when study completion occurs.
cEnd of trial occurs at the last visit or last scheduled procedure for the last patient.Study CompletionbPatient and investigator 
agree to discontinue  
study treatmentStudy treatmentContinued access 
follow -up
(approximately 30 days)Continued Access Period a
End of Trialc
I5B-MC-JGDP(e)Clinical Protocol Page 53
LY30122078.Discontinuation Criteria
8.1.Discontinuation from Study Treatment
8.1.1.Discontinuation of All Study Treatment
Patients will be discontinued from all study treatment in the fo llowing circumstances listed 
below.  The reason for discont inuation and the date of di scontinuation will be collected for all 
patients:
the patient is enrolled in any  other clinical  trial involving an invest igational product or any  
other type of medical research judged not to be scient ifically or medically co mpatible with 
thisstudy
the patient becomes pregnant during the study
the patient is significant lynoncompliant with study procedures
disease progressi on
unacceptable toxicit y
the patient, for any reason, requi res treatm ent with another therapeuti c agent that has been 
demonstrated to be effect ive for treatment of the study  indication.  Discontinuat ion from 
study treatmentwill occur prior to introduction of the new agent .
the investigator decides that the patient should be discontinued fro m study treatment
the patientrequests to be discont inued from study treatment
the patient’s designee (for example, parents, legal guardian, or caregiver) reque sts that the 
patient be discont inued from study treatment
Patients who are di scontinued from study treatmentwill have fo llow-up procedures performed as 
shown in the Schedule of Act ivities(Section 2).
8.1.2.Discontinuation of Olaratumab /Placebo
Patients will be discontinued from olaratumab if they  experience unacceptable toxicit y or 
experience an AE that would require a dose reductio n below the doses listed in TableJGDP.9.
8.1.3.Discontinuation of Inadvertently Enrolled Patients
If Lillyor the invest igator ident ifies a patient who did not meet enrollment criteria and was 
inadvertent ly enrolled, a discussio n must occur between the Lilly CRP and the invest igator to 
determine if the patient may continue in the study .  If both agree i t is medically  appropriate to 
continue, the invest igator must obtain documented approval fro m the LillyCRP to allow the 
inadvertent ly enrolled patient to continue in the study  with or without study treatment.
8.2.Discontinuation from the Study
Patients will be discontinued from the study in the following circumstances:
participation in the study needs to be stopped for medical, safet y, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
the investigator decides that the patient should be discontinued fro m the study
I5B-MC-JGDP(e)Clinical Protocol Page 54
LY3012207the patient requests to be discont inued from the study
the patient’s designee (for example, parents, legal guardian, or caregiver) requests th at the 
patient be discont inued from the study
Patients who discont inue fromthe study early will  have end-of-study procedures perform ed as 
shown in the Schedule of Act ivities(Section 2).
8.3.Lost to Follow -Up
A patient will be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by [CONTACT_4145].  Study site personnel are expected to m ake 
documenteddiligent attempts to contact [CONTACT_57986] a scheduled visit or who 
the site is otherwise unable to fo llow-up.
Study site personnel , or an independent third party , will attem pt to collect the survival status for 
all randomizedpatients who are lost to fo llow-up, including rando mizedpatients who do not 
receive study  treatment, withinlegal and ethical boundaries.
Public sources may  be searched for survivalstatus inform ation.  If the patient ’s survivalstatus is 
determined, the survivalstatus will be documented, and the patient w ill not be considered lost to 
follow-up.
Lilly personnel will not be invo lved in any attempts to collect survivalstatus inform ation.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188091] results.  Certain 
samples ma y be retained for a longer period, if necessary, to comply with applicable laws, 
regulations, or laboratory  certificat ion standards.
9.1.Efficacy Assessments
Tumor assessments will be performed according to Response Evaluat ion Criteria In Solid 
Tumors Version 1.1 (RECIST 1.1 )for each patient at the times shown in the Schedule of 
Activities(Section2).  Digital images are to be sent to a third -party organization for storage.
For patients with solid tum ors, computed tom ography (CT) scans, including spi[INVESTIGATOR_15143], are the 
preferred m ethods of m easurement (CT scan thickness reco mmended to be 5 mm); however, 
magnetic resonance imaging ( MRI)is also acceptable i n certain situat ions and if there is a 
concern about radiat ion exposure associated with CT.  Intravenous and oral contrast isrequired 
unless medically  contraindicated.
The CT portion of a positron emission tomography (PET) -CT scan may be used as a method of 
response assessment if the site can document that the CT is o f identical diagnostic qualit y to a 
diagnostic CT (with intravenous and oral contrast). A PET scan alone or as part of a PET -CT 
may be performed for addit ional analyses but cannot be used to assess response according to 
RECIST v.1.1 (Eisenhauer et al. 2009) .
Patients will be treated until there is documented radio logical PD, toxi city requiring cessation of
treatment, withdrawal of consent, or until other withdrawal criteria are met. In the event there is
symptomatic deterioration result ing in treatment discontinuation, radiographic confirmat ion
should be perform ed. For patients who discont inue treatment for any  reason other than
radiographically  documented PD (for exam ple, symptom atic deterioration), radiographic
assessments should cont inue as scheduled every 8weeks (±7 days) as calculated fro m
randomization until objective radiographic evidence of PD.
The method of tum or assessment used at baseline must be used consistently throughout the 
study.  Radio logical scan of the thorax, abdomen, and pelvis is required.
See Section 10.3.1for definitionsof the efficacy endpo ints.
9.1.1.Appropriatenes s of Assessments
The measures used to assess safet y and efficacy in this study  are consistent wi th those used in 
most convent ional oncology trials.
I5B-MC-JGDP(e)Clinical Protocol Page 56
LY30122079.2.Adverse Events
9.2.1.Definitions
An adverse event ( AE)is any untoward medical occurrence in a pat ient administered a 
pharmaceut ical product and that does not necessarily have a causal relat ionship with this 
treatment.  An AEcan therefore be any  unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally  associated with the use of a m edicinal 
(investigational) product, whether or not related to the medicinal (invest igational) product.
A treatment-emergent adverse event (TEAE) is an untoward medical occurrence tha t emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatm ent state, and does not necessarily  have to have a causal relat ionship with this 
treatment.
9.2.2.AE Reporting
The invest igator will use NCI-CTCAE version 4.03 (2010)to assign AE term s and severit y 
grades.  Documentation should include onset and reso lution/stabilization dates, AE grade, 
seriousness, relationship to study  treatment, and outcome of the event. AE reporting will begin 
after the pati ent signs the ICF.
Investigators are responsible for:
monitoring the safet y of patients in this study  and for al erting Lillyor its designee to any  
event that seems unusual, even if this event may be considered an unanticipated benefit 
to the patient
the appropriate medical care of patients during the study
documenting their review of each laboratory  safety report
following, through an appropriate health care option, AEs that are serious or otherwise 
medically important, considered related to study  treatment or the study, or that caused 
the patient to discont inue study  treatmentbefore complet ing the study.  The patient 
should be followed until the event resolves, stabilizes with appropriate diagnostic 
evaluation, or is reasonably  explained.  Frequency of f ollow-up evaluat ion is left to the 
discretion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record v ia eCRF the occurrence and nature of 
each patient’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addition, study site personnel  will record via eCRFany 
change in the preexisting condit ions and any new condit ions as AEs.   Investigators should record 
their assessment of the potential relatedness of each AE to study  procedure or study  treatment via 
eCRF.
The invest igator will interpret and docum ent whether or not an AE hasa reasonable possibilit y 
of being related to study  treatment or a study  procedure, taking into account the disease, 
I5B-MC-JGDP(e)Clinical Protocol Page 57
LY3012207concomitant treatments ,or pathologies. A “reasonable possibilit y” means that there is a cause 
and effect relat ionship between the study  treatment and/or study  procedure and the AE.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
Study site personnel  must report any  dose modifications or treatm ent discont inuations that result 
from AEs to Lillyor its designee via eCRF, clarifying, if possible, the circumstances leading to 
thedose modification ordiscontinuation of treatment.
Adverse event will be co llected until at least [ADDRESS_1188092] dose of study  treatment.  After 
the 30-day short-term follow-up visit, only new and ongoing serious adverse events (SAEs) 
deemed related to study  treatment will be collected .
9.2.3.Serious Adverse Events
An SAE is any  AE from this study  that results in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacity
congenital ano maly/birth defect
considered signific ant by [CONTACT_92355]:  important medical events 
that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_848412], based upon appropriate medical judgment.
Although all AEs after signing the ICF are recorded in the eCRF, SAE reporti ng begins after the 
patient has signed the ICF and has received study  treatment.  However, if an SAE occurs after 
signing the ICF, but prior to receiving study  treatment, i t needs to be reported ONLY if it is 
considere d reasonably  possibly related to study  procedure.
Study site personnel  must notify Lillyor its designee of any SAE within 24hours of investigator 
awarenessof the event via a Lilly -approved m ethod.  If alerts are i ssued via telephone, they are 
to be immediately followed wit h official notification on study -specific SAE forms.   This 24-hour 
notification requirement refers to the init ial SAE informat ion and all fo llow-up SAE information.
Pregnancy (during maternal or paternal exposure to study  treatment) does not meet the definit ion 
of an AE but shoul d be reported.  However, to fulfill regulatory  requirements any  pregnancy 
should be reported following the SAE process to collect data on the outcome for both mother and 
fetus.
Investigators are not obligated to actively seek AEs or SAEs in pat ients once they  have 
discontinued and/or completed the study  (the patientsummary eCRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patient has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study  participation, the invest igator must promptly notify Lilly .
I5B-MC-JGDP(e)Clinical Protocol Page 58
LY3012207Planned hospi [INVESTIGATOR_853607] t he 
patient’s medical history  at the time of enrollment should not be considered SAEs.  
Hospi[INVESTIGATOR_246638] a preci pi[INVESTIGATOR_4596] (for 
example, for the administration of study  treatment or other protocol -requiredprocedure) should 
not be considered an SAE.
Serious adverse events, including death, caused by [CONTACT_853633].
9.2.4.Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to study  treatment or study  procedure.  
[LOCATION_002] 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory  requirements in parti cipating countries 
require the reporting of S[LOCATION_003]Rs .  Lilly has procedures that will be followed for the recording 
and expedited reporting of SUS ARs that are consistent with glo bal regulat ions and associated 
detailed guidances.
9.2.5.Adverse Events of Special Interest
Adverse events of special interest (AESIs) are events that have been ident ified as safet y signals 
during preclinical or early  clinical tri als or based on class effects of similar drugs.  These events 
will be mo nitored prospectively in the clinical developmental program.  Each event is defined by  
a careful assessment and groupi[INVESTIGATOR_327767] (MedDRA ™)preferred terms.
Infusion-related reacti ons(IRRs)to olaratumab.As with other monoclonal 
antibodies, hypersensit ivity reactions (including fatal reactions) have been 
reported with olaratumab administration.
IRRsto nab-paclitaxel.  Severe and fatal hypersensit ivity reactions have been 
reported with administration of nab-paclitaxel.
Pneumonitis–Pneumonitis (including fatal cases) ha sbeen reported in patient 
receiving nab-paclitaxeland gemcitabine.
Refer to Section 7.4for specialtreatment considerations for dose del ays, modifications, and 
discontinuat ions from olaratumab/placebo and nab-paclitaxel /gemcitabine, including adverse 
events of concern or special interest.   For olaratumab IRRs, refer to Section7.[IP_ADDRESS] for
instructions on the m onitoring and subsequent d osing and prem edication adjustments for patients 
who experience an IRRto olaratumab.
9.2.6.Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of studyparticipants, m onitor quality, and to 
facilitate process and product improvements.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188093] Labelfor the specific agent.
9.4.Safety
9.4.1.Other Safety Measures
For each patient, electrocardiograms ( ECGs), vital signs, laboratory  tests, or other tests should be 
collected as shown in the Schedule of Activities (Section 2).  ECGs will be co llected centrally 
for patients in the Phase [ADDRESS_1188094] ion. 
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary . 
Collection of more ECGs than expe cted at a parti cular time point i s allowed when needed to 
ensure high qualit y records.
Electrocardiograms will be interpreted by  a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible , and ideally while the 
patient is still present, to determine whether the patient meets entry criteria and for immediate 
patient management, should any  clinically relevant findings be identified.   Any clinically 
significant findings that result in a diagn osis and that occur after the patient receives the first 
dose of study  treatmentshould be reported to Lilly or its designee as an AE via eCRF.
9.4.2.Safety Monitoring
Lilly willperiodically review evolving aggregate safet y data within the study  by [CONTACT_81132].  The LillyCRP will monitor safety data throughout the course of the study .The Lilly
CRP will review trends in safet y data, laboratory analytes, and AEsincluding monitoring o f 
AESIs.  Lillywill review SAEs wit hin time frames mandated by  [CONTACT_10984].
A safety review co mmittee (SRC) consist ing of the Lilly CRP /CRS, Global Patient Safety (GPS)
physician, statist ician, the primary  investigator, and ad hoc SCR members as needed will be 
responsible for review of safet y data.  The SRC will convene to review data at the end of the 
DLT observat ion periodafter Phase 1b is complete prior to initiationof Phase 2.
In the event that safet y monitoring uncovers an issue that needs to be addressed by [CONTACT_129219], only members of the Independent Data Monitoring Committee (IDMC) (refer to 
Section10.3.5) can conduct addit ional analyses of the safet y data.
During the study , Lilly will perform a blinded review of all reports of deaths and SAEs to ensure 
completeness and accuracy.  If a death or other clinical AE is deemed serious, unexpected, and 
I5B-MC-JGDP(e)Clinical Protocol Page 60
LY3012207possibly related to study  treatment, a limited number of Lilly  GPS representatives external to the 
study team will be unblinded for regulatory  reporting and safet y monitoring purposes.  These
measures will preserve the integrit y of the data collected during this study  and minimize any  
potential for bias while providing for appropri ate safety monitoring.
[IP_ADDRESS]. Hepatic Monitoring
If a patient experiences elevated ALT 5 × ULN and elevated total biliru bin 2 × ULN, clinical 
and laboratory  monitoring should be initiated by [CONTACT_3170].
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.To ensure patient safety and comply wit h regulator y guidance, the 
investigator is to consult with the Lilly CRP regarding collect ion of specific reco mmended 
clinical informat ion and follow-up laboratory  tests.  Refer to Appendix 5 .
9.5.Pharmacokinetics
Pharmacokinet ic samples will be collected as specified in the Pharmacokinet ic, Immunogenicit y, 
and Biomarker Research Sampling Schedule ( Appendix 4 ).  Based on the time and dates 
specified in Appendix [ADDRESS_1188095] specimen drawn to reduce the potential for a diluted or 
improperly drawn sample.  The actual date and time (24 -hour clock time) of each sampling will 
be recorded.
These samples will be analyzed at one or more laboratories designated by [CONTACT_11007].  Serum 
concentrations of olaratumab will be assayed using a validated enzyme-linked immunosorbent 
assay method.
Drug concentration informat ion that could unblind the study  will not be reported to i nvestigative 
sites or blinded personnel unt il the study has been unblinded.
The PKsamples will be stored at a facilit y designated by [CONTACT_11007].  The rem aining serum and 
plasma from the samples collected for PK may be pooled and used for exploratory  drug 
metabolism work and other exploratory PK/pharmacodynamic work as deemed appropriate.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188096] patient visit for the study , or for a shorter period if local 
regulationsand/or ethical review boards ( ERBs)impose shorter time limit s, at a facilit y selected 
by [CONTACT_11007].  This retenti on period enables use of new techno logies, response to questions fro m 
regulatory agencies, and invest igation of variable response that may not be observed unt il later in 
the development of olaratumabor after olaratumab becomes commercially available.
Molecular techno logies are expected to improve during the [ADDRESS_1188097] ion.
9.8.Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, pharmacodynamics (PD), mechanism of act ion, variabilit y of patient response 
(including safet y), and clinical out come.  Sample collect ion is incorporated into clinical studies 
to enable examinat ion of these questions through measurement of bio molecules including DNA, 
RNA, proteins, lipi[INVESTIGATOR_805], and other cellular elements.
Samples for bi omarker research , described in Section9.8.2,will be collected as specified in
Appendix [ADDRESS_1188098] already been generated from 
samples that were collected and analyzed prior to enro lling in this trial.  This may include data 
generated fro m genetic analyses.  If available, these data may b e requested fro m medical records 
for use in the research described in Section 9.8.2.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188099] ion of an addit ional biopsy specimen and blood sample after treatment 
with study drug(s) has been init iated, including potent ially after disease progressi on.Such 
additional biopsies shoul d be performed only if they do not create undue risk to the patient. If 
these additional samples are requested, they  will be used to further invest igate molecular features 
that may explain treatment response and resistance mechanisms.
9.8.1.Samples for Non pharmacogenetic Biomarker Research
Blood samples for nonpharmacogenetic bio marker research will be co llected as specified in 
Appendix 4 ,where local regulations allow.
Samples will be examined for bio markers related to , but not limited to the drug targets, disease 
process, immune cells/immune and tumor microenvironment functioning within the disease state 
and/orcancer-related condi tions, pathway  associated with cancer and study  drugs, variable 
response to olaratumab and/or nab -paclitaxel and gemcitabine , the mechanism  of action of study 
drugs, and/or for research -related methods, or validating diagnostic tools or assays.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_327790].
Samples will be retained for a m aximum of [ADDRESS_1188100] patient visit for the study , or 
for a shorter peri od if local r egulations and/or ERBs impose shorter time limits, at a facilit y 
selected by  [CONTACT_11007].  This retenti on period enables use of new techno logies, response to questions 
from regulatory  agencies, and invest igation of variable response that may not be observed unt il 
later in the development of olaratumabor after olaratumabbecomes commercially available.
9.8.2.Tissue Samples for Research
Phase 1b
Collection of the fo llowing tum or tissue samples is optional for all patients participating in 
Phase 1b:
an archived FFPEtumor tissue sample, if not restricted by  [CONTACT_853634] .  
Note:  if sufficient archival t issue not available, a new biopsy is not required.
Phase 2
Collection of the fo llowing tum or tissue samples is required for all rando mized pat ients in 
Phase2 in order to participate in this study :
an archived FFPEtumor tissue sample;if such tissue is not available ,a newly 
obtained core or excisio nal biopsy of atumor lesion must be perform ed.
In addition to the required tumor tissue and bio marker samples discussed above, patients may be 
asked to undergo collect ion of an addit ional biopsy specimen and blood sample after treatment 
with study drug(s) has been init iated, including potent ially after disease progressi on.Such 
additional biopsies shoul d be perform ed only if they do not create undue risk to the patient. If 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188101] s 
associated with pancreatic cancer and/or cancer -related condit ions, immune cells/immune and 
tumor microenvironment functioning wit hin the disease state and/or cancer -related condi tions, 
mechanism o f actionof olaratumab and/or gem citabine, nab-paclitaxel,and/or research methods 
or in validating diagnostic tools or assay (s) related to cancer.   The analysis o f these tumor tissue 
samples mayinclude the assessment of expressio n of PDGFRα, P DGFRβ, and canonical ligands 
(PDGFA, B, C, and D ).
Formalin-fixed paraffin -embedded tum or tissue obtained fro m the primary tumor or metastatic 
site should be provi ded as a blo ck or unstained slides.  Due diligence should be used to make 
sure that tumor sam ple (not a norm al adjacent or a tum or margin sample) i s provided.  Pathol ogy 
report accompanying archival t issue may also be requested. The report must be coded with the 
patient number. Personal ident ifiers, including the patient’s name [CONTACT_133430], must be removed 
from the institutional pathol ogy report pri or to submissio n.  Archivalblocks will be sect ioned 
and returned to the study  site. Slides and t issue samples co llected on -study will not be returned.
Samples will be retained for a m aximum of [ADDRESS_1188102] patient visit for the study, or 
for a shorter peri od if local regulations and/or ERBs impose shorter time limits, at a facilit y 
selected by  [CONTACT_47551] i ts designee.  This retention period enables use of new technologies, response 
to questions from regulatory agencies, and investigation of variable response that may not be 
observed unt il later in the development of olaratumab or after olaratumab becomes co mmercially 
available.
Technologies are expected to improve during the [ADDRESS_1188103] ing techno logies, including mutation profiling, copy  number 
variability, gene expressio n, multiplex assays, and/or immunohistochemistry ,may be performed 
on these tissue samples to assess p otential associations with these bio markers and clinical 
outcomes.
9.8.3.Immunogenicity Assessments
Blood samples for immunogenicit y testing will  be collected as shown in Appendix [ADDRESS_1188104] anti -drug antibodies in the presence of olaratumab.  
Antibodies may be further characterized and/or e valuated for their abilit y to neutralize the 
activity of olaratumab.
When possible ,immunogenicit y analysis will be done fro m the same blood drawn for PK 
analysis. In the event of an o laratumab/placebo infusion react ion, additional blood samples will 
be collected for addit ional immunogenicit y analysis. These addit ional samples will be co llected 
as close as possible to the onset of the event, at the point of resolut ion from the event, and within 
30 days after onset of the event.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188105] the pati ent visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
[CONTACT_11007].  The duration allows Lilly to respond to future regulatory  requests related t oolaratumab.
9.9.Patient-Reported Outcomes /Resource Utili zation(Phase 2 only )
9.9.1. P atient-Reported Outcomes
In the Phase 2 portion of this study , patient-reported outcome (PRO) for pain will be assessed
using the Brief Pain Inventory  Short Form, Modified ( mBPI-sf; Cleeland 1991).  Health -related 
quality of life will be assessed with the European Organisat ion for Research and Treatment of 
Cancer Qualit y of Life Quest ionnaire Core 30 ( EORTC QLQ- C30; Aaronson et al. 1993).  
Health status will be assessed using the EuroQol 5-Dimensio n 5-Level (EQ-5D-5L).  For the 
mBPI-sf, [ADDRESS_1188106] cy cle 
(not on Cy cle1 Day1) and the second one at Day  [ADDRESS_1188107] be completed prior to study  drug administration.
Patient-reported questionnaires should be completed by [CONTACT_853635] a language translat ion is 
available in which the pat ient is fluent or literate.
[IP_ADDRESS]. Pain assessments
The mBPI-sf is an 11-item instrument used as a mult iple-item measure of cancer pain intensit y.  
In addition to pain intensit y (4 items), the m BPI-sf is designed for patients to record the presence 
of pain in general, pain relief, and pain interference with funct ion (general act ivity, mood, abili ty 
to walk, ability to perform normal work, relat ions with others, sl eep, and enjo yment of life).  The 
mBPI-sf is administered per the Schedule of Activities(Section 2).  The recall period is the past 
[ADDRESS_1188108] week and complet ion time is ty pi[INVESTIGATOR_897] 5 to 7 minutes.
Responses for the mBPI -sf items are captured through the use of 11 -point numeric rating scales 
anchored at 0 ( no pain ordoes not interfere ) and ranged through 10 ( pain as bad as you can 
imagine orcompletely interferes ).  The focus of the analysis will be on the “worst pain”.  “Worst 
pain” intensit y has been shown to meaningfully impact pat ients’ lives as indicated by  a strong 
correlation with functional interference scores in various ty pes of cancer (Daut et al . 1983; 
Serlinet al. 1995; Ger et al. 1999; McMillan et al. 2000; Shi et al. 2009).  Moreover, a study  by 
[CONTACT_853636]. (2004) sugge sted that patients’ tendency to focus on the most severe level o f pain 
I5B-MC-JGDP(e)Clinical Protocol Page 65
LY3012207during a recall period may bias average recalled pain. Therefore, t he focus of the analysis will 
be on the “worst pain”.
Analgesic use will be recorded on the eCRF.  Data on each indiv idual prescript ion and 
over-the-counter analgesic medicat ion will be recorded on the Concomitant Medicat ions eCRF,
including but not limited to drug name [CONTACT_853647].  The use of analgesics should 
be reviewed with the patient during each vis it.  Any changes to analgesic use (new or stopped 
analgesics) will be recorded on the eCRF.  Analgesics will be classified into [ADDRESS_1188109] 
cycle(not on Cycle1 Day1)and the second one at Day  [ADDRESS_1188110] cy cleprior to study  
treatment administration .The baseline mBPI -sf score will be calculated as the average of the 2 
baseline asse ssments. 
The mBPI-sf population will include all pat ients who com pleted the baseline assessment 
(2assessments within 7 days of Cycle1 Day1) followed by [CONTACT_2669] 1 mBPI -sf “worst pain” 
assessment after 1 cycle of study  drug(Cycle2 Day1 or later).
Table JGDP. 12. World Health Organization Pain Scale
CodeDescription
0No analgesia
1Aspi[INVESTIGATOR_248] (for pain, not cardiovascular prophylaxis), acetaminophen, nonsteroidal anti -inflammatory drugs
2Codeine, hydrocodone, pentazocine, oxycodone
3Oral morphine, hydromorphone, methadone, transdermal fentanyl
4Parenteral opi[INVESTIGATOR_858]
5Neurosurgical procedures (blocks)
[IP_ADDRESS]. EORTC QLQ- 30
Broadly used in cancer trials, validated, and available in over 80 different languages, the EORTC
QLQ-C30 is a reliable and validated tool. The EORTC QLQ -C30 v3.0 i sa self-administered, 
cancer-specific questionnaire wit h multidimensio nal scales. The EORTC QLQ-C30 self-
reported general cancer instrument consists of 30 items covered by 1 of 3 dimensi ons:
global health status/qualit y of life (2 items)
functional scales (15 total items addressing eit her physical, role, emotional, cognit ive, or 
social functioning)
symptom scales (13 total items addressing either fatigue, nausea/vomit ing, pain, dyspnea, 
insomnia, appetite loss, constipat ion, diarrhea, or financial impact)
The EORTC QLQ-C30 questionnaire is administered per the Schedule of Activities (Section 2).  
The recall period is the past week, complet ion time is ty pi[INVESTIGATOR_897] 5 to 7 minutes, and the
questionnaire will be scored as described by [CONTACT_240230] (Fayers 2001).   The 
QLQ-C30 population will include all pat ients who com pleted the baseline assessment (Cycle 1
I5B-MC-JGDP(e)Clinical Protocol Page 66
LY3012207Day1) followed by [CONTACT_2669] 1 QLQ -C30assessment after 1 dose of study drug (Cycle 2 Day 1 or
later).
[IP_ADDRESS]. EQ-5D-5L
The EQ-5D-5L is a standardized instrument for use as a measure of self -reported heal th status
(Herdman et al. 2011).  Specifically, this quest ionnaire is included in this trial to evaluate 
health-state utilit ies associated with metastatic pancreatic cancer.  These utilit y measures are an 
important input for economic evaluat ions concerning the value of treatment in terventions.
The EQ-5D-5L is designed to be used in conjunct ion with other patient -reported measures.  
Patients will complete the 5 -dimension (mobility, self-care, usual act ivities, pain/discomfort, and 
anxiety/depression), 5-level (no problem, slight, mod erate, severe, or extreme problem) 
assessment according to the Schedule of Activities(Section 2).  A unique EQ -5D health state is 
defined by [CONTACT_240231] 1 level from each of the 5 dimensions. Additionally, patients will indicate 
their current health status by  [CONTACT_240232] a visual analogue scale ranging fro m 100 (best 
imaginable healt h state) to 0 (worst imaginable healt h state).
The recall period is “t oday.”  The EQ -5D-5L is designed for self -completion taking only  a few 
minutes to complete.
The EQ-5D-5L populat ion will include all pat ients who completed the baseline assessment 
(Cycle 1Day 1) followed by [CONTACT_2669] 1 EQ-5D-5Lassessment after 1 dose of study  drug(Cycle 2 
Day 1 or later) .
EQ-5D-5L responses may be incorporated into cost utilit y analyses, but will not be included in 
the clinical study  report.
9.9.2.Resource Utili zation
Investigators will be asked to document the use of best supportive care (BSC) measures,
concomitant medicat ions, transfusio ns, and treatment -related hospi[INVESTIGATOR_240185]. Such
assessments are to be taken throughout the study  through the 30 -day short-term
postdiscont inuation follow-up visit.
I5B-MC-JGDP(e)Clinical Protocol Page 67
LY301220710.Statistical Considerations
10.1.Sample Size Determination
The Phase 1b portion of the study  will sequentially evaluate twoalternative dosing schedules 
using a “3 + 3”dose-escalation design.  Based upon the design, the Phase 1b portion may enroll 
up to approximately 24patientsto determine the dose and regimen for olaratumabin 
combination with nab-paclitaxel and gemcitabinerecommended for use in the Phase 2 portion of 
the study.
The Phase 2 portion of the study will enroll approximately  162additional patients, randomized
in a 1:[ADDRESS_1188111] to efficacy in this study .  The purpose of this interim analysis is solely  to inform  
decision-making regarding whether or not to init iate early development of  a separate Phase3 
trial.
Assuming the trueOS HRis 0.67, there is at leas t 80% statistical power at a 1-sided significance 
level of 0.10 (or equivalent ly a 2-sided significance level o f 0.20) to show a statist ically 
significant differ ence in OS between study  arms.
Researchers have reported a median OS of 8.5 months in pancreatic cancer patients receiving 
gemcitabine plus nab -paclitaxel versus 6.7 m onths with gemcitabine alone (Von Hoff et al . 
2013).  If the control arm in the current study  performs similarly, the me dian OS for the 
experimental arm would be approximately  12 to 13 m onths, consistent with an HR of 0.67. 
Efficacy analysis will be based on intent -to-treat analyses.  In addit ion, the safet y analysis 
requires only 1dose of study  drug to be included ,thus patients excluded should be minimal.
10.2.Populations for Analyses
Phase 1b
DLT-evaluable Population :  The DLT -evaluable populat ion will include all enrolled patients 
who complete Cycle 1 or di scontinue due to a DLT prior to complet ing Cycle 1 treatment.
Safetypopulation:  All enrolled pat ients who receive any  quantity of study treatment, regardl ess 
of their eligibility for the study , will be included in the safety  analysis.  Safet y evaluation will be 
performed based on the actual init ial therapy a patient has received, regardl ess of any other 
cohort to which he or she was assigned.
Biomarker population:   will include the subset of patients fro m the ITT populat ion from who m 
a valid assay result has been obtained.  Samples for bio marker research will be collected at times 
specified in Appendix 4 , where local regulations allow.
I5B-MC-JGDP(e)Clinical Protocol Page 68
LY3012207Phase 2
Intention -to-Treat (ITT) population: will include all rando mized pat ientswhoreceived at 
least one dose of assigned treatment .  The ITT analysis o f efficacy data will consider allocat ion 
of patients to treatm ent groups as randomized and not by  [CONTACT_147246].  This 
population will be used for all baseline, efficacy, and healt h economics analyses .
Per-protocol population: will include all rando mized pat ients who receive at least 1doseof 
study treatmentand do not have any major protocol vio lations that coul d potentially affect the 
efficacy conclusions of the study .  This population will be defined in detail in the SAPprior to 
database lock .
Safety population:   will include all rando mized patients who received any  quantity of study 
treatment, regardless o f their eligibilityfor the study. The safety evaluation will be performed 
based on the first dose of study treatment a patient actually received, regardl ess of the arm  to 
which he or she was rando mized. The safety population will be used for all dosing/exposure, 
safety, and resource utilizat ion analyses.
Pharmacokinetic population:   will include all treated patients who received at least [ADDRESS_1188112] 1postbaseline evaluable PK sample.
Biomarker population:   will include the su bset of pati ents from the ITT population from who m 
a valid assay result has been obtained.   Samples for bio marker research will be collected at times 
specified in Appendix 4, where local regulations allow.
10.3.Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts designee.
Unless otherwise stated, all confidence intervals ( CIs)will be reported using a 2-sided95% level.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the SAP and the clinical study  report.  Addi tional exploratory analyses of the data will be 
conducted as deemed appropriate.
10.3.1.Efficacy Analyses
[IP_ADDRESS]. Primary Endpoint
Overall Survival
Overall survival is defined as the time from the date of randomization to the date of death from 
any cause.   For each patient, prior to each data analysis, a reasonable effort will be made to 
obtain the most up -to-date status of the patient (date of death or last date known to be alive).   If 
the patient is alive or l ost to follow -up at the time of data analysis, OS data will be censored on 
the last date the patient is known to be alive. For any patient who has withdrawn consent for 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188113] ratio between treatment arms 
will be estimated using a stratified Cox regressio n model (Cox 1972), stratified by  [CONTACT_64118]. Overall survival curves, the median and survival rates at various time 
points with 95% CI, for each treatment arm will be estimated using t he Kaplan -Meier method 
(Kaplan and Meier 1958).  Sensit ivity analyses for OS will be described in the SAP.
[IP_ADDRESS]. Secondary Endpoints
Progression -Free Survival
Progression -free survival is defined as the time from rando mization until the first radiographic 
documentation of progressi onas defined by [CONTACT_393] (Version 1.1)or death fro m any cause in 
the absence ofPD.  Patients who die wit hout a reported prior progression will be considered to 
have progressed on the day  of their death.  Pati ents who di d not progress or are lost to follow-up 
will be censored at the day  of their last radiographic tum or assessment. If no baseline or 
postbaseline radio logic assessment is available, the patient will be censored at the date of 
randomization. If death or PD occurs af ter [ADDRESS_1188114], stratified by  [CONTACT_853637].  The corresponding HR between treatment arms will 
be estimated using a stratified Cox regressio n model (Cox 1972), stratified by  [CONTACT_853638].  Progression -free survival  curves, m edian PFS, and PFS rates at various time po ints with 
95% CI for each treatment arm will be estimated using the Kaplan -Meier method (Kaplan and 
Meier 1958).  Sensit ivity analyses for PFS will be described in the SAP.
Objective Response Rate
Objective response rate is defined as the number of pat ients who achieve a best overall response 
of complete response (CR) or partial response (PR) from rando mization until PD/recurrence 
divided by [CONTACT_853639] (ITT 
population).  Patients who do not have a tumor response assessment for any reason will be 
considered non -responders and will be included in the deno minator when calculat ing the 
response rate.  The ORR, with 95% CI, will be summa rized for each treatment arm and 
compared between treatment arms using the Cochran -Mantel-Haenszel test adj usting for the 
randomization strata.
Duration of Response
Duration of response is defined as the time from the date measurement criteria for CR or PR
(whichever is first recorded) are first met until the first date that disease is recurrent or object ive 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188115] 1 dose of any study therapy will be evaluated for safet y and 
toxicity.
The MedDRA Versio n 19.1 or laterwill be used when reporting AEs by [CONTACT_133416].  The 
MedDRA Lower Level Term will be used in the treatment -emergent com putation.  Treatm ent-
emergent adverse events will be summarized by  [CONTACT_1196] (SOC) and by  [CONTACT_853640].
Phase 2
Safety analyses will include summaries of the fo llowing:
AEs, including severi ty and possible rel ationship to study  drug
SAEs, including possible relationship to study  drug
AEsleading to dose adjust ments
AESI
IRR
discontinuat ions from study treatment due to AEsor death
treatment-emergent abnormal changes in laboratory values
treatment-emergent abnormal changes in vital signs and ECGs
10.3.3.Other Analyses
[IP_ADDRESS]. Patient Disposition
A detailed description o f patient disposition will be provi ded, including a summary  of the 
number and percentage of patients entered into the study , enrolled in the study , and treated as 
well as number and percentage of patients completing the study , as defined in the SAP, or 
discontinuing (overall and by [CONTACT_702391]).  A summary o f all important protocol 
deviations will be provided.
[IP_ADDRESS]. Patient Characteristics
Demographic data are collected and reported to demo nstrate that the study  population represents 
the target patient populat ion considered for regulatory  approval.
A summary  of baseline pat ient and disease characteri stics, historical diagnose s, preexist ing 
conditions, and prior therapi[INVESTIGATOR_853608].
[IP_ADDRESS]. Concomitant Therapy
A summary  of prior and concomitant medications by [CONTACT_848452].
I5B-MC-JGDP(e)Clinical Protocol Page 71
LY301220710.3.3.4. Poststudy -Treatment -Discontinuation Therapy
The numbers and percentages of patients receiving poststudy -treatment-discontinuation 
anticancer therapi[INVESTIGATOR_242895] t ype of therapy (surgery, radiotherapy, or systemic 
therapy), and by [CONTACT_242946]/or nam e, overall and by [CONTACT_27939] .
[IP_ADDRESS]. Treatment Compliance
The number of cycles received, dose omissio ns, dose reductions, dose delays, and dose intensit y 
will be summarized for all treated patients by  [CONTACT_2939] .
Study treatment will be administered at the invest igator site, therefore treatment compliance is 
assured.
[IP_ADDRESS]. Pharmacokinetic Analyses
Pharmacokinet ic analyses will be conducted on patients who have received at least [ADDRESS_1188116] nonco mpartmental 
methods of analysis for olaratumab.  The maximum concentration (C max), time of C max(tmax), 
area under the concentration -time curve (AUC), half -life (t1/2), steady-state volume of 
distribution (Vss), clearance (CL), and other relevant parameters that can be calculated from the 
data will be reported from these nonco mpartmental analyses.
In the Phase 2 part, PK parameters for olaratumab (CL, exposure, V ss, and t 1/2) and 
inter-individual PK variabili tywill be computed using nonlinear mixed effect modeling 
implemented in NONMEM.  The versio n of any software used for the analysis will be 
documented and the program will meet the Lilly  requirements of software validation.
If warranted by [CONTACT_26739],PK/pharmacodynamic analyses using OS, PFS, and/or other appropriate 
clinical endpo ints will also be conducted to characterize the exposure -response relationship in 
this study.
[IP_ADDRESS]. Patient Reported Outcomes Analyses -Phase 2 only
Patient-reported outcomes are measured through the fo llowing:
mBPI-sf
EORTC QLQ -C30
EQ-5D-5L
For each instrument (mBPI -sf, EORTC QLQ -C30, and EQ -5D-5L), percentage compliance will 
be calculated as the number of completed assessments divided by [CONTACT_77431] o f expected 
assessments (that is, patients still on study  and alive).  Percentage compliance and reasons for 
non-compliance will be summarized by [CONTACT_692346] t ime point.
Data will be separately summarized by [CONTACT_853641]. The 
main efficacy measure for the pain endpo int will be the time to first worsening of the mBPI -sf 
“worst pain” score. Time to first worsening in pain will be described using the method of 
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188117].  
“Worsening” will be defined as eit her a “worst pain” increase o f >2 points postbaseline or an 
analgesic drug class increase of >1 level(Farrar et al . 2001; Rowbotham  2001).  However, other 
approaches to defining clinically me aningful worsening in pain might be considered.  Further 
detailswill be provided in the SAP.
Additionally, time to first worsening of QLQ-C30 scale scores(see Section [IP_ADDRESS]) will be 
analyzed using Kaplan -Meier and Cox methods. Further statistical analysis to be performed for 
PROs will be defined and detailed in the SAP.
The EQ-5D-5L responses may be incorporated into a cost -utility analyses but w ill not be 
included in the clinical study  report. 
[IP_ADDRESS]. Biomarker Analyses
The markers in peripheral blood, plasma, serum, and tumor that may  indicate 
pharmacodynamics/tailoring effect of olaratumab or the combinat ion partners may be explored 
and characterized by [CONTACT_853642].
See Section 9.8for details reg arding bio marker evaluat ion.
[IP_ADDRESS]. Healthcare Resource Utilization
Hospi[INVESTIGATOR_602], transfusio ns, and concomitant medicat ions during study  treatment will be 
summarized descript ively by [CONTACT_2939].
Investigators will be asked to document the use of best suppo rtive care measures, conco mitant 
medications, transfusio ns, and treatment -related hospi[INVESTIGATOR_30874].  Such assessments are to be 
taken throughout the study  through the [ADDRESS_1188118] been observed among Phase 2 patients .  The interim 
analysis will not be used for purposes of formally testing any efficacy  hypotheses .
The results from the interim analyses will be examined by [CONTACT_853643] (i DMC).The membership, roles, and responsibilit ies of the of the iDMC will be 
defined in the SAP or iDMC Charter. The iDMCwill review unblinded data. Information that 
may unblind the study  during the analyses will not be reported to study  sites or blinded study  
team members unt il the study has been unblinded.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188119] patient has 
been enro lled if deemed appropriate by [CONTACT_1034].
I5B-MC-JGDP(e)Clinical Protocol Page 74
LY301220711.References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, 
Fleishman SB, de Haes JC, et al. The European Organizat ion for Research and Treatment of 
Cancer QLQ -C30: a qualit y-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst . 1993;85(5):365 -376.
Abraxane® (nab -paclitaxel) Prescribing Informat ion. Summit, NJ: Celgene Corporati on; revised 
July 2015 . http://www.abraxane.co m/wp-
content/uploads/Abraxane_Prescribing_Informat ion.pdf. Accessed May 16, 2016.
[ACS] American Cancer Societ y. Cancer Facts & Figures 2016 . Atlanta: Ameri can Cancer 
Society; 2016. Available at: 
http://www.cancer.org/acs/groups/con tent/@research/documents/document/acspc -047079.pdf . 
Accessed [ADDRESS_1188120], Brookl and RK, Washington MK, Gershenwald JE, 
Compton CC, Hess KR, Sullivan DC, Jessup JM. AJCC Cancer Staging Manual , 8thed. 
Springer, New  York. 2017.
Cleeland CS. Brief Pain Inventory -Short Form©Copyright 1991 Charles S. Cleeland, PhD, Pain 
Research Group; Interactive Performance Techno logies, LLC.
Cancer Research [LOCATION_006] (WWW). Pancreati c cancer stati stics.Available at: 
http://www.cancerresearchuk.org/health -professional/cancer-statistics/statistics-by-cancer-
type/pancreat ic-cancer. Accessed 07 September 2016.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum creatinine. Nephron. 
1976;16:31 -41.
Conroy T, Dessei gne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, 
Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa -Akouz F, Péré -
Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto- Grillot C, Ducreux M; 
Groupe Tumeurs Digest ives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus 
gemcitabine for metastati c pancreat ic cancer. N Engl J Med . 2011;364(19):[ADDRESS_1188121]. Regression models and life -tables. J Royal Stat Soc Ser B . 1972;74(2):[ADDRESS_1188122] ions of energy at various ages from internal 
photon sources. I.Methods. Oak Ridge National Laborator y. Published date: April 1987; 
ORNL/TM -8381/V1.
[CTCAE] Cancer Therapy  Evaluation Program , Common Terminology Criteria for Adverse 
Events, DCTD, NCI, NIH, DHHS . Version 4.0 published: May 28, 2009(version 4.03: June 
14, 2010).
Daut RL, Cleeland CS, Flanery  RC. Devel opment of  the Wisconsin Brief Pain Questionnaire to 
assess pain in cancer and other diseases. Pain.1983;17(2):197 -210.
Ebert M, Yokoy ama M, Fri ess H, Kobrin MS, Büchler MW, Korc M. Induction of platelet -
derived growth factor A and B chains and over -expressio n of their receptors in human 
pancreatic cancer. Int J Cancer . 1995;62(5):529-535.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188123] R, Dancey  J, Arbuck S, 
Gwyther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (versio n 1.1). 
EurJ Cancer. 2009;45(2) 228 -247.
ErkanM, Michalski CW, Rieder S , Reiser-ErkanC, Abiatari I, Kolb A, Giese NA, Esposito I, 
Friess H, Kleeff J. The activated stroma index is a novel and independent prognostic marker in 
pancreatic ductal adenocarcino ma.ClinGastroenterol Hepatol. 2008;6(10):1155- 1161.
FarrarJT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in 
chronic painintensity measured on an 11- point numerical painrating scale. Pain.
2001;94(2):149-158.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf o f the 
EORTC Qualit y of Life Group. The EORTC QLQ -C30 Scoring Manual (3rd Edition). 
Published by: [CONTACT_67383], Brussels 2001 .
Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyam oto Y, Tsuji  S, Nakajima S, 
DoiR, Imamura M. Expressio n of two angiogenic factors, vascular endothelial growth factor 
and platel et-derived endothelial cell growth factor in human pancreat ic cancer, and its 
relationship to angiogenesis. Eur J Cancer . 1998;34(9):1439-1447.
Ger LP, Ho ST, Sun WZ, Wang MS, Cleeland CS. Validat ion of the Brief Pain Inventory  in a 
Taiwanese popul ation.J Pain Symptom Manage .1999;18(5):[ADDRESS_1188124]: a histopathological prognostic parameter for tumor recurrence and tumor death 
within three years after the init ial operation. Jpn J Cancer Res . 1997;88(6):590 -599.
HerdmanM, Gudex C, Llo yd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development 
and preliminary  testing of the new five -level version of EQ- 5D (EQ-5D-5L). Qual Life Res . 
2011;20(10):1727 -1736.
Kaplan EL, Meier P. Nonparametric estimat ion of incomplete observ ations. J Amer Stat Assoc . 
1958;53:457 -481.
Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty  B. Targeting the platelet derived growth factor 
receptor α with a neutralizing human mo noclonal antibody inhibits the growth of tumor 
xenografts: implicat ions as a potential therapeut ic target. Mol Cancer Ther . 
2005;4(3):369-379.
Mahadevan D, Von Hoff DD. Tumor- stroma interactions in pancreat ic ductal adenocarcino ma.
Mol Cancer Ther . 2007;6(4):1186 -1197.
McMillan SC, Tittle M, Hagan S, Laughlin J. Management of pain a nd pain-related symptom s in 
hospi[INVESTIGATOR_240194].Cancer Nurs .2000;23(5):327 -336.
[NCI] National Cancer Institute. Cancer Therapy Evaluat ion Program , Common Terminology 
Criteria for Adverse Events, Version 4.0, DCTD, NCI, NIH, DHHS. 2009. Pub lish date: 
29May 2009.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicit y 
and response criteria of the eastern cooperative oncology  group. Am J Clin Oncol . 
1982;5:649 -655.
I5B-MC-JGDP(e)Clinical Protocol Page 76
LY3012207Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain. 2001;94(2):131 -132.
[SEER] Surveillance, Epi[INVESTIGATOR_145975], and End Resul ts Program , National Cancer Institute. SEER 
Stat Fact Sheets: Pancreas Cancer. 2016. Available fro m URL:
http://seer.cancer.gov/statfacts/ht ml/pancreas.ht ml. Accessed 21 March 2016.
SerlinRC,Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, 
moderate or severe? Grading pain severit y by [CONTACT_240258]. Pain.
1995;61(2):277-284.
Shi Q,Wang XS, Mendoza TR, Pandya KJ, Cleeland CS. Assessing persistent cancer pain: a 
comparison of current painratings and painrecalled from  the past week. JPainSymptom 
Manage. 2009;37(2):[ADDRESS_1188125] ics, 2016. CA Cancer J Clin. 2016;66(1):7 -30.
Stone AA, Broderick JE, Shiffman SS, Schwartz JE. Understanding recall o f weeklypainfrom a 
momentary assessment perspective: abso lute agreement, between -and within -person 
consistency, and judged change in weekly pain. Pain. 2004;107(1- 2):61-69.
[TCGA] The Cancer Geno me Atlas, National cancer Insti tute. Available at:
http://cancergeno me.nih.gov/.
Tempero MA, Arno letti JP, Behrman S, Ben -Josef E, Benson AB 3rd, Berlin JD, Cameron JL, 
Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshino ff BW 2nd, 
Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, 
WhitingS, Willett C, Wolff RA. Pancreatic Adenocarcino ma.J Natl Compr Canc Netw . 
2010;8(9):972 -1017.
Von Hoff DD, Ram anathan RK, Borad MJ, Laheru DA, Smit h LS, Wood TE, Korn RL, Desai N, 
Trieu V, Iglesias JL, Zhang H, Soon -Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. 
Gemcitabine plus nab -paclitaxel is an active regimen in pat ients with advanced pancreat ic 
cancer: a phase I/II trial . J Clin Oncol. 2011;29(34):4548-4554.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Mo ore M, Seay  T, Tjulandin SA, 
MaWW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary  N, Ramanathan RK, 
Tabernero J, Hidalgo M, G oldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF.
Increased survival in pancreat ic cancer with nab -paclitaxel plus gemci tabine. N Engl J Med . 
2013;369(18):1691 -1703.
World Cancer Research Fund Internat ional (WWW). Pancreat ic cancer statist ics. Available at: 
http://www.wcrf.org/int/cancer -facts-figures/data -specific-cancers/pancreat ic-cancer-statistics. 
Accessed 07 September 2016.
I5B-MC-JGDP(e)Clinical Protocol Page 77
LY3012207Appendix 1. Abbreviations and Definitions
Term Definition
AEAdverse event:  any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and that does not necessarily have a 
causal relationship with this treatment.  An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory find ing), symptom, 
or disease temporally associated with the use of a medicinal (investigational) product, 
whether or not related to the medicinal (investigational) product.
α-galgalactose-α-1-3-galactose
AESIadverse event of special interest
ALTalanine aminotransferase
ANCabsolute neutrophil count
ASTaspartate aminotransferase
AUCarea under the serum concentration time curve
blinding/maskingA procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment.  Unless
otherwise specified, blinding will remain in effect until final 
database lock.
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
BSA body surface area
CI confidence interval
Cmax maximum concentration
CIOMS CouncilforInternational Organizations ofMedicalSciences
CL clearance
CNS central nervous system
collection database a computer database where clinical trial data are entered and validated.
CR complete response
CRP Clinical research physician:  Individual responsible for the medical conduct of the 
study.  Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician, or other medical officer.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188126]
FDA Food and Drug Administration
GCP good clinical practice
G-CSF granulocyte -colony stimulating factor
GF growth factor
GPS Global Patient Safety
I5B-MC-JGDP(e)Clinical Protocol Page 79
LY3012207highly effective 
method of 
contraceptioncombined oral contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382], NuvaRing®, implantable contraceptives, 
injectable contraceptives (such as Depo -Provera®), intrauterine device (such as 
Mirena®and ParaGard ®), contraceptive patch for women <90 Kg (<198 pounds), total 
abstinence, or vasectomy
A highly effective method of contraception is defined as one that results in a low failure 
rate (that is, <1% incidence of pregnancy per year) when used consistently and 
correctly, such as contraceptive implants, injectables, combined oral estrogen or 
progestogen -only contraceptives associated with inhibition of ovulation, some 
intrauterine contraceptive devices (IUDs), total abstinence, or a vasectomized partner.
For patients using a hormonal contraceptive method, information regarding the study 
drugs under evaluation and their potential effect on the contraceptive should be 
addressed.
Abstinence as a method of birth control is acceptable if it is the established and 
preferred method of contraception for the patient.
Also see the definition of effective method of contraception.
HR hazard ratio
IAC Internal Assessment Committee
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference forHarmonisation
IgE Immunoglobulin E
IgG1 immunoglobulin G su bclass 1
interim analysis An interim analysis is an analysis of clinical trial data conducted before the final 
reporting database is created/locked.
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRR infusion-related reaction
ITT intention-to-treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
I.V. intravenous(ly)
IVRS/IWRS interactive voice -response sy stem/interactive web -response system
I5B-MC-JGDP(e)Clinical Protocol Page 80
LY3012207MedDRA Medical Dictionary for Regulatory Activities
mBPI-sf Brief Pain Inventory Short Form Modified
Menopause include women with either:
(1) spontaneous amenorrhea for at least 12 months, not induced by a medical condition 
such as anorexia nervosa, and not taking medications during the amenorr hea that 
induced the amenorrhea (for example, oral contraceptives, hormones, GnRH, 
antiestrogens, selective estrogen receptor modulators, or chemotherapy), or
(2) spontaneous amenorrhea for 6 to 12 months and a follicle -stimulating hormone level 
>40mIU/mL.
MTD maximum tolerated dose . MTD is the highest dose of a drug or treatment that does not 
cause unacceptable side effects.
NCI National Cancer Institute
ORR objective response rate
OS overall survival
PD progressive disease
PDGF platelet-derived growth factor
PDGFRα platelet-derived growth factor receptor alpha
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetics
PR partial response
PRO patient-reported outcome
PT prothrombin time
PTT partial thromboplastin time
Randomize the process of assigning patients to an experimental group on a random basis
RECIST Response Evaluation Criteria in Solid Tumors
reporting database A point-in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
re-screen to screen a patient who was previously declared a screen failure for the same study
SAE serious adverse event
SAP Statistical Analysis Plan
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188127] of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.
screen failure Patient who does not meet one or more criteria required for participation in a trial
SD stabledisease
SOC system organ class
SRC Safety Review Committee
STS soft tissue sarcoma
S[LOCATION_003]Rs Suspected unexpected serious adverse reactions
t1/2 half-life
TEAE Treatment-emergent adverse event :   an untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment .
US [LOCATION_002]
Vss steady-statevolume of distribution
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188128] igator is responsible for:
ensuring that the patient understands the potential risks and benefits of participat ing in 
the study
ensuring that informed consent is given by [CONTACT_240256], where permitted by  [CONTACT_853644].  This includes obtaining the appropriate signatures and 
dates on the ICF prior to the performance of any  studyprocedures and prior to the 
administration of study  treatment.
answering any quest ions the pati ent may have throughout the study  and sharing in a 
timely manner any  new inform ation that may be relevant to the patient’s willingness to 
continue his or her participat ion in the trial.
Ethical Review
Documentation of ERB approva l of the protocol and the ICF must be provided to Lillybefore the 
study may begin at the investi gative site(s).  Lillyor its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  Al l ICFs 
must be compliant with the ICH guideline on GCP.
The study  site’s ERBs shoul d be provi ded with the following:
the current IB or package labeling, Patient Information Leaflet, Package Insert, or 
Summary  of Product Characteristics and updates during t he course of the study
the ICF
relevant curri cula vitae
Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m international ethics guidelines, including the 
Declaration of Helsinki and Council f or Internati onal Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines 
applicable ICH GCP Guidelines
applicable laws and regulations.
Some obligations of Lilly may be assigned to a third-party organizat ion.
Investigator Information
Physicians with a specialt y in Oncologywill participateas investigators in this clinical trial.
I5B-MC-JGDP(e)Clinical Protocol Page 83
LY3012207Protocol Signatures
Lilly’sresponsible medical officer will approve the protocol, confirming that, to the best of his 
or her knowledge , the protocol  accurately describes the planned design and conduct of the study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lillyrepresentative.
Final Report Signature
[CONTACT_702405], indicating agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study . 
The invest igator with the mostenrolled pat ients will serve as the clinical study  report 
coordinat ing investigator.  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  [CONTACT_853645].
The Lillyresponsible medical officer and statist ician will approve the final clinical study  report 
for this study, confirming that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
Data Quality Assur ance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provide instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  Thi s session 
will give instruction on the protocol, the completion of the CRFs, and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in data 
collection
conduct a qualit y review of the database
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source docume nts at the study  site.  The study  may be audited by [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The investigator will keep records of all original source data.  Thi s might includelaboratory  
tests, medical records, and clinical notes.  If requested, the invest igator will provide Lilly
applicable regulatory  agencies, and applicable ERBs with direct access to original source
documents.
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188129] data or ECG data, will be stored electronically in the 
central vendor’s database system.  Data will subsequent ly be transferred from the central vendor 
to the Lilly data warehouse .
Any data for which the paper documentation provided by [CONTACT_853646] i dentified and documented by  [CONTACT_129240]’s study  file.  Paper 
documentation provided by [CONTACT_81146], for example, a paper di ary to collect pati ent-
reported outcome (PRO) measures (for example, a rating scale), a daily dosing schedule, or an 
event diary.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem.
Study and Site Closure
Discontinuation of Study Sites
Study site participation may be discont inued if Lilly or its designee, the invest igator, or the ERB
of the study  site judges it necessary for m edical, safety, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regulatory, or other reasons consistent with applicable laws, regulat ions, andGCP.
I5B-MC-JGDP(e)Clinical Protocol Page 85
LY3012207Appendix 3. Clinical Laboratory  Tests
All laboratory  screening evaluat ions are to be performed within 28days prior to 
enrollment/rando mization, unless otherwise specifie d.  Eligibility for inclusio n in this clinical 
trial will be based on l ocal clinical laboratory  results (not transcribed onto eCRFs); duplicate 
samples will be submitted to the central laboratory where indicated below .  For patient and study  
site convenien ce and safet y, treatment decisions may be based upon results of tests performed 
locally.  Discrepancies between local and central laboratory  that may have an impact on 
eligibility or treatment decisions will not be considered protocol deviat ions.  On-studyclinical 
laboratory  tests assayed for patient safet y (such as hematology , serum chemistry , coagulation, 
and pregnancy  tests) are to be collected prior to study  treatment.
I5B-MC-JGDP(e)Clinical Protocol Page 86
LY3012207Clinical Laboratory Tests
Hematology a
Leukocytes (WBC) Erythrocytes (RBC)
Neutrophils , segmented and band forms Hemoglobin
Lymphocytes Hematocrit
Monocytes Mean corpuscular volume (MCV)
Eosinophils Mean corpuscular hemoglobin concentration (MCHC)
Basophils Platelets
Coagulationc
aPTTor PTT
INRor PT
Clinical Chemistry a
Serum Concentrations of:
Alanine aminotransferase (ALT) Cholesterol
Albumin Creatine kinase (CK)
Alkaline phosphatase Creatinine
Aspartate aminotransferase (AST) Glucose random, nonfasting
Bilirubin, direct Magnesium
Bilirubin, total Potassium
Blood urea nitrogen (BUN) Sodium
Calcium Uric acid
CA-19.9c,e
Urinalysis c
Blood Protein
Glucose Specific gravity
Ketones Urine leukocyte esterase
pH
Pregnancy Testc
Serum pregnancy test (females only)b
Urine pregnancy test,c,d
Abbreviations:  ALT = alanine aminotrans ferase; AST = aspartate aminotransferase ; BUN = blood urea nitrogen; 
CA19.9 = cancerantigen 19.9 ; INR= International normalized ratio; PT = prothrombin time; PTT = partial 
thromboplastin time; RBC = red blood cell s; WBC = white blood cells.
aTests performed at local laboratories for patient enrollment/management/safety must submit duplicate samples 
for testing at a Lilly-designated laboratory.
bSerum pregnancy test will be performed at screening on women of childbearing potential .  If the baseline serum 
test is positive, a repeat serum and urine pregnancy test will be done; if those results are positive, the investigator 
is to consult with the Lilly clinical research physician or scientist regarding if dosing should occur and which 
follow-up laboratory tests are performed.
cLocal or investigator -designated laboratory .
dWhile on-study, urine pregnancy test will be performed in females of childbearing potential only on D ay1 of 
every cycle or per local practic e (whichever is of shorter duration) and at short -term follow -up visit.  If the urine 
pregnancy test performed on D ay1 of each cycle is positive, confirm with a serum pregnancy test.
eCA-19.9 will be collected on Day 1 of each cycle.  
I5B-MC-JGDP(e)Clinical Protocol Page [ADDRESS_1188130] infusio n start and stop times (actual clock readings )are recorded.  
The exact time of co llection of each venous blood sample will be based on the cloc k used to 
record infusio n times.  It is essent ial that the pharmacokinet ic blood sam ples not be wi thdrawn 
from the same site as the drug infusio n.
For samples co llected within the first 24 hours ofthe respective olaratumab administration , 
sample collection times may  vary ±10% or as specified in the PK sampling schedule.
I5B-MC-JGDP(e)Clinical Protocol Page 88
LY3012207Pharmacokinetic , Immunogenicity, and Biomarker Research Sampling Schedule –Phase 
1b(Cohorts 1and 2)
Cycle Day Dosing Sampling TimeOlaratumab
PKa, cPlasma for 
BiomarkersWhole 
Blood for 
PGx eIGb, c
Screening 0-28 X
11Prior to olaratumabdX X X
Olaratumab(1 hr)
≤ [ADDRESS_1188131] -olaratumab X
Observation(1 hr)
60 ± [ADDRESS_1188132]-
olaratumabX
4 ± 0.[ADDRESS_1188133] -olaratumab X
2 24 ± [ADDRESS_1188134] -olaratumab X
5 Anytime X
8Prior to olaratumabdX X
Olaratumab(1 hr)
≤ [ADDRESS_1188135] -infusion X
15Prior to olaratumabdX X X
Olaratumab(1 hr)
≤ [ADDRESS_1188136] -infusion X
Observation(1 hr)
60 ± [ADDRESS_1188137] -
olaratumabX
nab-Paclitaxel (0.5hr)
2 ± 0.[ADDRESS_1188138] -nab-
paclitaxelX
16 24 ± [ADDRESS_1188139] -olaratumab X
19 Anytime X
22 Anytime X
21Prior to olaratumabdX X X
Olaratumab(1 hr)
8Prior to olaratumabdX
Olaratumab(1 hr)
15Prior to olaratumabdX
Olaratumab(1 hr
≤ [ADDRESS_1188140] -infusion X
31Prior to olaratumabdX X X
Olaratumab(1 hr)
≤ [ADDRESS_1188141] -olaratumab X
60 ± [ADDRESS_1188142] -
olaratumabX
4 ± 0.[ADDRESS_1188143] -olaratumab X
2 24 ± [ADDRESS_1188144] -olaratumab X
5 Anytime X
8Prior to olaratumabdX
Olaratumab(1 hr)
≤ [ADDRESS_1188145] -olaratumab X
15Prior to olaratumabdX
Olaratumab(1 hr)
≤[ADDRESS_1188146] -infusion X
60 ± [ADDRESS_1188147] -
olaratumabX
4 ± 0.[ADDRESS_1188148] -olaratumab X
16 24 ± [ADDRESS_1188149] -olaratumab X
17 Anytime X
19 Anytime X
4 1 Prior to olaratumabdX
5 and then 
every other 
cycle1 Prior to olaratumabdX X
30-day 
follow-up 
visitAnytime XX
X
I5B-MC-JGDP(e)Clinical Protocol Page 89
LY3012207Abbreviations:  I G= immunogen icity; IRR = infusion-related reaction; PK = pharmacokinetic.
aSamples of approx imately3 mL of whole blood will be drawn without anticoagulant for meas urement of olaratumab in 
serum.
bFor the immunogenicity assay for IgE anti -α-gal antibody screening , approx. 10mL of whole blood will be drawn.
cIf a patient experiences an IRR to olaratum ab/placebo, blood samples for immunogenicity and PK analysis will be taken at 
the following time points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 days 
(±3 days) after the IRR.
dPretreatment samples may be collected any time during the day of the clinical visit, prior to the start of the olaratumab 
infusion and must be taken prior to administering any premedication .
I5B-MC-JGDP(e)Clinical Protocol Page 90
LY3012207Pharmacokinetic , Immunogenicity, and Biomarker Research Sampling Schedule –Phase 
2
Cycle Day Dosing Sampling TimeOlaratumab
PKa, cPlasma for 
BiomarkersWhole 
Blood for 
PGxeIGb, c
Screening 0-28fX
11Prior toolaratumab/placebodX X X
Olaratumab(1 hr)
≤[ADDRESS_1188150] -
olaratumab/placeboX
8Prior toolaratumab/placebodX X
Olaratumab(1 hr)
≤[ADDRESS_1188151] -
olaratumab/placeboX
15Prior to olaratumab
dose/placebod XXX
Olaratumab(1 hr)
≤[ADDRESS_1188152] -
olaratumab/placeboX
nab-Paclitaxel (1 hr)
≤[ADDRESS_1188153] -nab-paclitaxel X
21Prior toolaratumab/placebodX X X
Olaratumab(1 hr)
≤[ADDRESS_1188154] -
olaratumab/placeboX
8Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188155] -
olaratumab/placeboX
15Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188156] -
olaratumab/placeboX
31Prior toolaratumab/placebodX X X
Olaratumab(1 hr)
≤[ADDRESS_1188157] -
olaratumab/placeboX
8Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188158] -
olaratumab/placeboX
15Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188159] -
olaratumab/placeboX
4 1 Prior to olaratumab/placebodX
5 and then every 
other cycle1 Prior toolaratumab/placebodX X
30-day follow -up 
visitAnytime XXX
Abbreviations:  I G= immunogen icity; IRR = Infusion -related reaction; PK = pharmacokinetic.
aSamples of approximately 3 mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in 
serum.
bFor the immunogenicity assay for IgE anti -α-gal antibody screening , approx. 10mL of whole blood will be drawn.
cIf a patient experiences an IRR to olaratum ab/placebo, blood samples for immunogenicity and PK analysis will be taken at 
the following time points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 days 
(±3 days) after the IRR.
dPretreatment samples may be collected any time during the day of the clinical visit, prior to the start of the olaratumab 
infusion and must be taken prior to administering any premedication .
eSample colle cted predose Cycle [ADDRESS_1188160] not started treatment during the temporary hold, the screening window will be 
extended an additional 14 -days.
I5B-MC-JGDP(e)Clinical Protocol Page 91
LY3012207Appendix 5. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormali ty and may 
be required in fo llow-up with patients in consultat ion with the Lilly clinical research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin (HGB)
Hematocrit (HCT) Hepatic Coagulation a
Erythrocytes (RBC) Prothrombin time (PT)
Leukocytes (WBC) Prothrombin time, INR
Neutrophils b
Lymphocytes Hepatic Serologies a,c
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets (PLT) Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
Alanine aminotransferase (ALT) Recommended Autoimmune Serology:
Aspartate aminotransferase (AST) Anti-nuclear antibody a
Gamma-glutamyl transferase ( GGT) Anti-smooth muscle antibody a
Creatine phosphokinase (CPK) Anti actin antibody a
Abbreviations:  CRF=case report form; IgG =immunoglobulin G; IgM =immunoglobulin M; INR=international 
normalized ratio; RBC=red blood cells; WBC = white blood cells.
aAssayed by [CONTACT_11007] -designated laboratory.
bNeutrophils reported by [CONTACT_831444].Whenever a manual differential is needed to report the neutrophils, the segmented and band forms should 
be added together and recorded on the CRF, unless the CRF specifically provides an entry field f or bands.
cReflex/confirmation dependent on regulatory requirements and/or testing availability.
I5B-MC-JGDP(e)Clinical Protocol Page 92
LY3012207Appendix 6. Creatinine Clearance Formula
Note:  This formula is to be used for calculat ing creatinine clearance (CrCl) fro m local 
laboratory results only.  
For serum creatinine concentration in 
mg/dL:
CrCl =
(mL/min) (140 –agea) (wta)    0.85 (if female) , or1.0 (if male)
72serum creatinine (mg/dL)
For serum creatinine concentration in mol/L:
CrCl  =
(mL/min)(140 –agea) (wta)  0.85 (if female) , or1.0 (if male)
0.81serum creatinine (mol/L)
Abbreviations:  CrCl = creatinine clearance; wt = weight.
aAge in years, weight in kilograms.
Source:  Cockcroft and Gault 1976.
I5B-MC-JGDP(e)Clinical Protocol Page 93
LY3012207Appendix 7. Protocol A mendment I5B -MC-JGDP(e) 
Summary :  A Phase 1b (Open -Label) / Phase 2 
(Randomized, Double -Blinded) Study  Evaluating Nab -
Paclitaxel and Gemcitabine With or Without Olaratumab in 
the Treatment of First -Line Metastatic Pancreatic Cancer
Overview
Protocol I5B-MC-JGDP: A Phase 1b (Op en-Label) / Phase 2 (Rando mized, Double -Blinded) 
Study Evaluating Nab-Paclitaxel and Gemcitabine Wit h or Without Olaratumab in the Treatm ent 
ofFirst-Line Metastatic Pancreatic Cancer )has beenamended.  The new protocol is indicated by  
[CONTACT_61504] (e) and will be used to conduct the study  in place of any preceding version o f the 
protocol.
The protocol was amended to include screening criteria for IgE antibodies against α-gal and 
premedication requirements to mit igate the risk for an observed rate of Grade ≥3 IRRs on 
StudyJGDP that was greater than the rate of 3.1% previously observed across the olaratumab 
program.
The changes made to this protocol are as fo llows: 
Key/Clarifying Changes:
Updatedanexclusion criterion for patients who have levels of IgE antibodies against 
α-galgreater than the upper limit of normal (Section6.2).
Removed an exclusio n criterion for patients receiving warfarin (Sect ion6.2).
Updated Premedication Cycle 1 guidelinesfor olaratumab/ placebo to include 
premedication 30-[ADDRESS_1188161]
(Section7.1.1.1). 
Updated tables for PK, Immunogenicit y, and Bio markerResearch Sampling Schedule to 
include IgE anti-α-gal antibody screening for Phase 1b and 2 and alter the screening 
window in Phase 2 (Appendix 4 ).
…
I5B-MC-JGDP(e)Clinical Protocol Page 94
LY3012207Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Additions have been identified by  [CONTACT_58002] .
Protocol I5B -MC-JGDP(de)
A Phase 1b (Open-Label) / Phase 2 (Randomized, 
Double-Blinded) Study  Evaluating Nab -Paclitaxel and 
Gemcitabine With or Without Olaratumab in the Treatment of 
First-Line Metastatic Pancreatic Cancer
5. Study Design
…
5.4.5. Rationale for Amendment ( e)
Amendment (e) updates the protocol to include screening criteria for Immunoglobulin E (IgE) 
antibodies against galactose -α-1-3-galactose (α -gal) and premedicat ion requirements to mit igate 
the risk for an observed rate of Grade ≥3 infusion -related reacti ons(IRRs) on Study  JGDP that 
was greater than the rate of 3.1% previously observed across the olaratumab program.  Based on 
data from  the Phase 1 and Phase 2 portion of Study  JGDP, Grade ≥3 IRRs were observed at an 
approximate rate between 5% and 10% of olar atumab-treated pati ents.
Infusion related reacti ons are a known Adverse Drug Reaction for olaratumab, and the rate of 
IRR is 12.5% (all grades) and 3.1% (Grade ≥3).  Grade ≥[ADDRESS_1188162] ic reaction is associated with elevated IgE 
antibody levels.  Across 8 studi es with olaratumab (401 evaluable olaratumab -treated pati ents), 
IgE antibody  levels greater than the manufacturer -specified ULN had a posit ive predict ive value 
of 75% (34.9% -96.8%) and a negative predict ive value of 99% (98.2% -99.9%) for Grade ≥3 
IRRs, with sensitivity of 75% (34.9% -96.8%) and specificit y of 99% (98.2% -99.9%).  Two 
patients had Grade ≥3 IRR wi th an IgE antibody  level ≤ ULN (0.28 kU/L and <0.10 kU/L, 
respectively).  Prior to this amendment, patients in Study  JGDP were tested for pre -existing IgE 
antibody against α-galas pre-planned retrospective analysis.  However, the results of these tests 
were not available prior to first dosing of o laratumab/placebo.   Pre-testing for elevated IgE 
antibody levels against -gal for all untreated pati ents as part of screening is being implemented 
as a risk mit igation strategy .
This amendment implements actions to mit igate the risk of increased Grade ≥3 IRRs observed in 
Study JGDP.  Specifically , screening in the Phase 2 portion of the study  was modified to i nclude 
immuniogenicit y testing, and the inclusio n/exclusion criteria wer e updated to clarify  that patients 
I5B-MC-JGDP(e)Clinical Protocol Page 95
LY3012207with IgE anti-α-gal antibody levels greater than the upper limit of normal will be excluded from  
this study.  In addition, the requi red premedication regimen prior to Cy cle 1 Day  1 of 
olaratumab/placebo was clarified to i nclude:  dexamethasone (or steroid equivalent); a histamine 
H1 antagonist ist (for example, di phenhydramine); and a histamine H2 antagonist (for example, 
ranitidine).  
6. Study Population
…
6.2. Exclusion Criteria
…
[25]haveknown allergy to nab-paclitaxel, gemcitabine,or olaratumab (l evels of 
IgE antibodi es against α-galthat are above the upper limit of normal) or any 
ingredient of olaratumab, nab-paclitaxel, or gemcitabineformulations.
[30] are currently  receiving warfarin and are unable to be switched to low 
molecular weight heparin or oral Factor II or Xa inhibitor with half -life less 
than [ADDRESS_1188163] dose of study  
treatment.
…
7. Treatments
…
7.1. Treatments Administered
…
7.1.1. Premedication
…
[IP_ADDRESS]. Olaratumab/Placebo
Infusion-related reacti ons(IRRs), including Grade ≥[ADDRESS_1188164] been observed with 
olaratumab. To date, all Grade ≥[ADDRESS_1188165] 
included flushing, shortness of breath, bronchospasm, fever/chills, and in severe cases have 
manifested as severe hypotensio n, anaphylact ic shock, or cardiac arrest. 
The following prem edications need to be adminis tered prior to olaratumab/placebo infusio ns in 
Study JGDP.Additional premedication may be provided at the invest igator’s discretion.
I5B-MC-JGDP(e)Clinical Protocol Page 96
LY3012207Premedication in Cycle 1:
Premedication is mandatory for allpatients during Cy cle 1 prior to each dose of 
olaratumab/placebo.Premedicate all pat ients with the following (or equivalent )
medications 30-60 minutes prior to olaratumab/placebo dosing on Days 1, 8, and 15 of 
Cycle 1:
oHistamine H1 antagoni st (for example, diphenhydramine)
oDexamethasone intravenously
oHistamine H2 antagon ist (for example, ranitidine)
Premedication in Cycles 2- n:
For subsequent cy cles, prem edication with a histamine H1 antagonist (for example, 
diphenhydramine) i s recommended prior to each dose of olaratumab/placebo.
…
I5B-MC-JGDP(e)Clinical Protocol Page 97
LY30122077.4.4. Dosing Disconti nuation
…
[IP_ADDRESS]. Olaratumab
…
[IP_ADDRESS].1. Olaratumab Infusion -Related Reactions
Olaratumab should be immediately  and permanently discontinued for Grade 3 or 4 IRR.  For 
olaratumab IRR treatm ent guidelines see Table JGDP.7. 
Due the observed rate of Grade ≥3 IRRs in the Phase 1 and Phase 2 portions of Study  JGDP that 
was greater than the rate of 3.1% previously observed across the olaratumab program , testing for 
IgE anti-α-gal antibodies mustbe performed as part of screening, and pat ient with antibody 
levels >ULN should be excluded.
…
Appendix 1. A bbreviations and Definitions
…
α-galgalactose-α-1-3-galactose
…
IgE Immunoglobulin E
…
Appendix 4. Pharmacokinetic, Immunogenicity , and 
Biomarker Research Sampling Schedule
…
I5B-MC-JGDP(e)Clinical Protocol Page 98
LY3012207Pharmacokinetic , Immunogenicity, and Biomarker Research Sampling Schedule –Phase 
1b(Cohorts 1 and 2)
Cycle Day Dosing Sampling TimeOlaratumab
PKa, cPlasma for 
BiomarkersWhole 
Blood for 
PGx eIGb, c
Screening 0-28 X
11Prior to olaratumabdX X X X
Olaratumab(1 hr)
≤ [ADDRESS_1188166] -olaratumab X
Observation(1 hr)
60 ± [ADDRESS_1188167] -
olaratumabX
4 ± 0.[ADDRESS_1188168] -olaratumab X
2 24 ± [ADDRESS_1188169] -olaratumab X
5 Anytime X
8Prior to olaratumabdX X
Olaratumab(1 hr)
≤ [ADDRESS_1188170] -infusion X
15Prior to olaratumabdX X X
Olaratumab(1 hr)
≤ [ADDRESS_1188171] -infusion X
Observation(1 hr)
60 ± [ADDRESS_1188172] -
olaratumabX
nab-Paclitaxel (0.5hr)
2 ± 0.[ADDRESS_1188173]-nab-
paclitaxelX
16 24 ± [ADDRESS_1188174] -olaratumab X
19 Anytime X
22 Anytime X
21Prior to olaratumabdX X X
Olaratumab(1 hr)
8Prior to olaratumabdX
Olaratumab(1 hr)
15Prior to olaratumabdX
Olaratumab(1 hr
≤ [ADDRESS_1188175] -infusion X
31Prior to olaratumabdX X X
Olaratumab(1 hr)
≤ [ADDRESS_1188176] -olaratumab X
60 ± [ADDRESS_1188177] -
olaratumabX
4 ± 0.[ADDRESS_1188178] -olaratumab X
2 24 ± [ADDRESS_1188179] -olaratumab X
5 Anytime X
8Prior to olaratumabdX
Olaratumab(1 hr)
≤ [ADDRESS_1188180] -olaratumab X
15Prior to olaratumabdX
Olaratumab(1 hr)
≤[ADDRESS_1188181] -infusion X
60 ± [ADDRESS_1188182] -
olaratumabX
4 ± 0.[ADDRESS_1188183]-olaratumab X
16 24 ± [ADDRESS_1188184] -olaratumab X
17 Anytime X
19 Anytime X
4 1 Prior to olaratumabdX
5 and then every 
other cycle1 Prior to olaratumabdX X
30-day follow -up 
visitAnytime XXX
Abbreviations:  IG = immunogenicity; IRR = infusion -related reaction; PK = pharmacokinetic.
aSamples of approximately 3 mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in 
serum.
I5B-MC-JGDP(e)Clinical Protocol Page 99
LY3012207bFor the immunogenicity assay for IgE anti -α-gal antibody screening , approx. 10mL of whole blood will be drawn.
cIf a patient experiences an IRR to olaratumab/placebo, blood samples for immunogenicity and PK analysis will be taken at 
the following time points:  (1) as soon as possible after the onset of the IRR , (2) at the resolution of the IRR, and (3) 30 days 
(±3 days) after the IRR.
dPretreatment samples may be collected any time during the day of the clinical visit, prior to the start of the olaratumab 
infusion and must be taken prior to administering any p remedication .
…
I5B-MC-JGDP(e)Clinical Protocol Page 100
LY3012207Pharmacokinetic , Immunogenicity, and Biomarker Research Sampling Schedule –Phase 
2
Cycle Day Dosing Sampling TimeOlaratumab
PKa, c Plasma for 
BiomarkersWhole 
Blood for 
PGx eIGb, c
Screening 0-28fX
11Prior toolaratumab/placebodX X X X
Olaratumab(1 hr)
≤[ADDRESS_1188185] -
olaratumab/placeboX
8Prior toolaratumab/placebodX X
Olaratumab(1 hr)
≤[ADDRESS_1188186] -
olaratumab/placeboX
15Prior to olaratumab
dose/placebod XXX
Olaratumab(1 hr)
≤[ADDRESS_1188187] -
olaratumab/placeboX
nab-Paclitaxel (1 hr)
≤[ADDRESS_1188188] -nab-paclitaxel X
21Prior toolaratumab/placebodX X X
Olaratumab(1 hr)
≤[ADDRESS_1188189] -
olaratumab/placeboX
8Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188190] -
olaratumab/placeboX
15Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188191] -
olaratumab/placeboX
31Prior toolaratumab/placebodX X X
Olaratumab(1 hr)
≤[ADDRESS_1188192] -
olaratumab/placeboX
8Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188193] -
olaratumab/placeboX
15Prior toolaratumab/placebodX
Olaratumab(1 hr)
≤[ADDRESS_1188194] -
olaratumab/placeboX
4 1 Prior to olaratumab/placebodX
5 and then every 
other cycle1 Prior toolaratumab/placebodX X
30-day follow -up 
visitAnytime XXX
Abbreviations:  IG = immunogenicity ; IRR = Infusion -related reaction; PK = pharmacokinetic.
aSamples of approximately 3 mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in 
serum.
bFor the immunogenicity assay for IgE anti -α-gal antibody screening , approx. 10mL of whole blood will be drawn.
cIf a patient experiences an IRR to olaratumab/placebo, blood samples for immunogenicity and PK analysis will be taken at 
the following time points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 days 
(±3 days) after the IRR.
dPretreatment samples may be collected any time during the day of the clinical visit, prior to the start of the olaratumab 
infusion and must be taken prior to administering any premedication .
eSample colle cted predose Cycle [ADDRESS_1188195] not started treatment during the temporary hold, the screening window will be 
extended an additional 14 -days.
Leo Document ID = 95b4c6d4-4d79-47e4-8835-85112b52e612
Approver: 
Approval Date & Time: 20-Mar-2019 13:57:21 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 20-Mar-2019 15:49:52 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]